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ABSTRACT 
 
Synthetic materials embedded with stimuli-responsive cleavable bonds have been 
extensively utilized for the development of site-targeted drug delivery system and 
selective imaging reporters. We developed stimuli-sensitive materials with two different 
redox switches including trimethyl-locked quinone propionic acid and nitrobenzyl 
moieties. Novel redox-sensitive polymeric nanoparticles and micelles were prepared from 
a synthesized monomer containing trimethyl-locked quinone propionic acid as a redox 
trigger. A hydrophobic cancer drug, paclitaxel, was incorporated into the redox-
responsive polymeric nanoparticles and micelles prepared from the synthesize polymers. 
The effect of redox stress on the nanoparticles and micelles was evaluated with a 
chemical reductant, sodium dithionite demonstrating that the significant amount of 
paclitaxel was released at a simulated redox-state compared to the control. Cell viability 
studies revealed that the polymer was non-toxic and the nanoparticles and micelles could 
release paclitaxel to suppress breast cancer cell growth.  In addition to the drug delivery 
system, a p-nitrobenzyl moiety redox trigger was utilized to develop a novel NIR 
fluorescent probe, p-nitrobenzyl 3,7-bis(dimethylamino)-10H-phenothiazine-10-
carboxylate for the selective imaging and therapy. Conjugating methylene blue with a p-
nitrobenzyl moiety enables it to quench electron transfer within the molecules. Moreover 
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the redox trigger caged probe released active methylene blue by nitroreductase-mediated 
1,6-elimination resulting exhibition of strong fluorescence (λmax = 680 nm) with the 
excitation at 580 nm. The fluorescence emission was also induced by incubation with live 
Escherichia coli bacteria. It was demonstrated that the NIR fluorescent probe generated 
singlet oxygen after nitroreductase mediated reduction with a laser irradiation at a 
wavelength of 634 nm. The redox trigger caged NIR fluorescent probe would be a 
suitable imaging sensor to detect bacteria expressing NTR. In addition, the probe also 
possesses potential as an MB prodrug which can be applied for the treatment of various 
diseases.  
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CHAPTER 1 
INTRODUCTION  
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 The aim of this chapter is to provide an insight into the principles behind the 
experimental work reported in this dissertation work. First, an introduction to redox 
microenvironment and its associated therapeutic opportunities are given, followed by an 
overview of redox triggers applied in the design of redox-responsive delivery system. 
The chapter concludes by discussing the advantages redox triggers may offer for targeted 
drug delivery systems and selective imaging.  
 Numerous modern drug delivery strategies seek to maximize the therapeutic 
potential of drug molecules at the targeted site and to minimize their side effects in 
healthy tissues. Potent anticancer therapeutic agents are generally non-selective to normal 
cells, leading to severe cytotoxic complication. Targeted drug delivery systems have been 
considered as a promising tool to alleviate such toxicity by distributing the cytotoxic 
drugs favorably to tumor sites in the body. For selective drug release in the desired site, 
stimuli-responsive polymer-based drug delivery systems have been extensively 
explored.1 The bioresponsive delivery systems can undergo conformational and/or 
physiochemical property changes and release incorporated drugs in response to the 
signals stemming from tumor microenvironments such as low pH2, altered oxidation-
reduction (redox)3, over-expressed enzymes4 and hyperthermia5. In addition to the 
targeted drug delivery system approach for the improvement of therapeutic effect, 
selective imaging is also pivotal in achieving accurate disease diagnostics and monitoring 
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therapeutic efficacy and processes. The key to an effective imaging strategy is the use of 
reporters that can be detected by various imaging devices. Radiotracers, magnetic probes 
and fluorescent agents are widely utilized reporters in research settings.6 Among these, 
the use of fluorophores is a promising tool for imaging due to advantages including high 
resolution, sensitivity and non-invasiveness.7 However, fluorescent probes with emission 
at short wavelengths have the limitation of poor tissue penetration owing to interference 
with the background auto-fluorescence from biomolecules.8 To overcome such 
limitations, fluorophores with emission in the far red and near-infrared (NIR), in the 
range of 600-1000 nm, have been investigated because absorption and autofluorescence 
are minimal in those wavelength ranges.9 Various approaches have been made to achieve 
selective imaging sensitivity of NIR fluorophores.10 Latent fluorescent probes, by virtue 
of being switchable/activatable, can be turned on by undergoing a user-designated 
chemical reaction triggered by specific stimuli. These activatable molecular probes 
improve the achievable target-to-background ratios. Such activatable probes are generally 
dependent on targeting groups such as a small molecules, peptides, and proteins.11 
Recently the altered redox status between intracellular and extracellular compartment has 
gained attention as an emerging strategy to achieve the targeted drug release and selective 
imaging.  
  
1.1. Cellular redox microenvironments and therapeutic opportunities 
Cellular metabolism and integrity are maintained by balancing the redox state of 
all the cellular components to maintain optimal overall functions. Redox homeostasis is 
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therefore vital to all organisms and is closely involved with redox reactions in which 
electrons and/or hydrogen atoms are transferred between donor and acceptor molecules. 
In response to redox imbalance, however, the redox gradient between intracellular and 
extracellular compartments becomes notably greater, which induces new metabolic 
pathways to restore optimal overall function. During these intracellular redox-regulatory 
processes, various redox agents are expressed12 and can serve as an important indicator of 
the redox status.13 In conjunction with the disease-related cellular redox changes, the 
redox gradient between intracellular and extracellular spaces has inspired the paradigm of 
redox-responsive biomaterials intended for intracellular drug delivery.14  
 
1.2. Redox triggers 
 Synthetic and macromolecular chemistry provides access to a wide range of 
redox-susceptible materials. Considering a number of redox agents expressed during the 
intracellular redox-regulatory pathways, it is crucial to select an appropriate redox trigger 
which responds specifically and selectively at the desired site of action for the responsive 
material architecture. Selected redox-triggers including disulfide, quinone and nitro 
compounds are discussed with their applications in biomedical materials as follows.   
 
 
1.2.1. Disulfide bond and glutathione  
A disulfide bond, formed through the oxidation of two thiols is a valuable 
functional group in a variety of chemical and biological agents exhibiting potent 
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reactivity or biological activities. This bond has already been found in proteins, oxidized 
glutathione, and even in numerous natural products including some drugs (e.g., 
mitomycin disulfides, leinamycin, etc.).15 In mildly oxidizing environments, the disulfide 
bond is relatively stable. However, disulfide bonds are rarely found inside cells, since 
disulfide bond can be easily cleaved by glutathione (GSH) which is the most abundant 
thiol-containing small molecule. In the human body, intracellular GSH concentration 
reaches 10 mM in cellular fluids while plasma and other body fluids drops the GSH 
concentration to 20 µM.16 In addition, tumor cells have also shown an elevated 
intracellular reduced glutathione concentration, a ~7-fold increase in vitro, in comparison 
with that of normal cells.17 Therefore, intracellular drug delivery has heavily taken 
 
Figure 1.1. The reduction of a disulfide substrate to free thiols. (i) Formation of a 
glutathione-substrate mixed disulfide and substrate free thiol; (ii) release of the second 
substrate free thiol and formation of GSSG; (iii) reduction of GSSG to GSH by GSSG 
reductase. 
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advantage of GSH-mediated thiol exchange. GSH can react with disulfide bonds through 
its cysteine-based thiol, which reduces the disulfide substrates to their corresponding free 
thiols and oxidizing glutathione to glutathione disulfide (Figure 1.1.). Because of this 
unique property of disulfide bond, it has been extensively applied for cancer research as 
an efficient redox trigger.  
 
  The disulfide chemistry applied for a 
variety of materials including prodrugs18, 
dendrimer19, liposome20, and polyplex for siRNA 
delivery21 could indeed release drug under 
elevated redox potential in tumor. Long et al. 
synthesized the disulfide-linked polyethylene 
glycol (PEG)−GSH conjugates 1 and 2 for GSH 
 
Figure 1.3. Chemical structure of 
disulfide linked-amphiphilic 
polymer.  
 
Figure 1. 2. GSH-transporter-targeted prodrug conjugates 1 and 2. 
 
7 
 
delivery (Figure 1.2).22 PEG is employed to protect the GSH moiety from oxidation until 
it is delivered into the cells. GSH is oxidized to GSSG during oxidative stress in cells, 
thereby restricting the oxidation of other molecules. Therefore, it plays an antioxidant 
role to protect cells from oxidative stress. When administered to the SH-SY5Y human 
neuroblastoma cell line under oxidative stress induced by H2O2, 1 did not display 
protecting activity against oxidative stress (Figure 1.2.). However, 2 was 100% effective 
on inhibition of oxidative stress since 2 enabled to release GSH via the reduction of its 
disulfide bond (Figure 1.2.). Further improvements in utilizing micelles that contain the 
S–S bond were investigated by Thayumanavan et al.23 In this study, a disulfide bond was 
exploited to conjugate the backbone chain to a hydrophobic alkyl chain resulting in the 
formation of micelle-like nanoassembly in aqueous media. In the presence of GSH, the 
doxorubicin loaded micelles were disassembled and thereby released the incorporated 
drug upon the solubility change in polymer after disulfide cleavage. It was demonstrated 
that the drug release from the micelles was dependent on the concentration of a reducing 
agent, GSH. However, these micelle-based approaches were not feasible to release drug 
release under tumor cell-relevant GSH levels. In addition, there have been many attempts 
to obtain dual-sensitivity by combining pH-sensitivity with disulfide-based redox-
sensitivity for selective tumor targeting.24 A disulfide group was also utilized for a redox-
responsive cross-linker to stabilize micellar structure and control the release of the 
encapsulated cargo in response to D,L-dithiothreitol.25  
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1.2.2. Trimethyl-locked quinone propionic acid and DT-diaphorase 
 Trimethyl-locked quinone propionic acid (QPA) group can undergo two-electron 
reduction by reducing agents to yield the respective hydroquinone propionic acid. The 
hydroquinone is immediately transformed into its corresponding lactone via intra 
molecular cyclization which eventually leads to the cleavage of any group linked through 
the carboxyl functionality as shown in Scheme 1.1. QPA can be reduced not only by 
chemical agents such as sodium dithionite and sodium borohydride but also by reductive 
enzyme, DT-diaphorase. 
 
 
Scheme 1.1. Chemical reduction of the trimethyl-locked QPA based redox-sensitive 
material. 
 
 DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO) (EC 1.6.99.2) is a 
cytosolic flavoprotein and was first isolated in 1958 by Lars Ernster.26 DT-diaphorase 
catalyzes the two-electron reduction of diverse substrates including quinones, quinone 
epoxides, aromatic nitro and nitroso compounds, azo dyes and Cr(VI) compounds using 
NADH or NADPH as electron donors. DT-diaphorase has been regarded as a 
chemoprotective enzyme capable of catalyzing the reduction and detoxification of 
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exogenous quinones. The enzyme is also known to be involved in the bioactivation of 
molecules such as MMC into toxic DNA-damaging agents. This enzyme is interestingly 
over-expressed in a number of tumor types, including non-small cell lung carcinoma, 
colorectal carcinoma, liver cancers, pancreatic cancers and breast carcinomas, when 
compared to normal tissues.27 In the case of non-small-cell-lung (NSCLC) tumors, DT-
diaphorase activity determined using 2,6-dichlorophenolindophenol was found to be 123 
nmol min-1 mg-1 compared to 6.4 nmol min-1 mg-1 in normal cells, a 20-fold increase28. 
Since DT-diaphorase detoxifies and protects the cell from toxins and mutagens, it tends 
to be expressed at higher levels in the early carcinogenic process. This upregulation may 
involve in epigenetic factors such as hypomethylation of DT-diaphorase gene, elevation 
of c-fos proto-oncogenes, altered promoter and/or repressor function.29 The previous 
study reported that it might play a role in the stabilization of tumor suppressor protein 
p53. Hence the last decade has seen increased focus on DT-diaphorase as an important 
target in oncology and a QPA group has potential to develop into an effective redox 
trigger to design redox-sensitive material in cancer research communities.  
10 
 
 Redox-triggered bioimaging probes composed of QPA have been synthesized to 
release fluorescent indicators after the DT-diaphorase-mediated activation. McCarley and 
coworkers have developed a QPA caged fluorophore using rhodamine (Figure 1.4.)30. It 
demonstrated that the QPA-based imaging probe generated fluorescence in the presence 
 
Figure 1.4. Activation of QPA caged fluorophore by human DT-diaphorase to yield the 
highly fluorescent dye, rhodamine. 
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of DT-diaphorase utilizing DT-diaphorase-positive human cancer cells. Moreover, redox-
sensitive self-immolative fluorophore was synthesized with a QPA trigger group, an N-
methyl-p-aminobenzyl alcohol self-immolative linker and naphothalimide fluorophore to 
detect DT-diaphorase levels for cancer diagnosis31. These studies investigated kinetics of 
DT-diaphorase with the redox-sensitive fluorophores and verified the selectivity of the 
QPA caged fluorophore to DT-diaphorase. However, monitoring fluorescence emission 
from these QPA caged fluorophores has not been accomplished. Recently Liu et al. 
synthesized DT-diaphorase-activatable theranostic prodrug which capable of assessing 
fluorescent emission to detect DT-diaphorase level.32 Camptothecin, an inhibitor of 
topoisomerase I, was selected as a fluorophore and its fluorescence was quenched by the 
covalently attached QPA trigger via photoinduced electron transfer (PET). The 
camptothecin released from the QPA caged fluorophore selectively destroyed the cancer 
which overexpresses DT-diaphorase with high efficacy.  
 
Figure 1.5. Activation of QPA caged self-immolative fluorophore by human DT-
diaphorase to yield the highly fluorescent dye naphothalimide. 
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 In addition to the QPA caged imaging probes, the QPA trigger was applied to the 
synthesis of prodrug for DT-diaphorase targeted release. A QPA-based aniline mustard 
prodrug synthesized by Volpato et al. had showed that cyclized product and the active 
drug were generated a time- and DT-diaphorase-dependent manner. The active drug 
exerted cytotoxicity on T47D cells upon  the reductive activation by oxidoreductases at 
low oxygen concentration33. The QPA trigger was also exploited to design redox-
triggered liposomes which electrochemically release chemicals. The liposomes were 
composed of 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and a QPA trigger 
attached to the head group of the lipid moiety.34 Chemical reduction-induced cyclization 
of QPA head group on the liposomes led to conformational change in the supramolecular 
assemblies, resulting in the release of encapsulated hydrophilic dye, calcein. Even though 
the QPA trigger has been extensively investigated in the development of redox-sensitive 
materials, it has never been introduced to a polymer network for drug delivery until our 
 
Figure 1.6. Activation of QPA caged self-immolative fluorophore by human DT-
diaphorase to yield the highly fluorescent dye naphothalimide. 
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group started to actively pursue the formulation of QPA based redox-sensitive polymer in 
2012. The approach with polymeric nanocarriers to deliver drug is advantageous over 
prodrugs and liposomes. Polymeric materials have a wide variety of available drug or dye 
selection to be incorporated inside them in spite of its hydrophobicity. Furthermore, the 
modification of polymers for further application in targeted delivery might be more easily 
achieved than prodrug or liposomes. 
 
1.2.3. Nitrocompounds and Nitroreductase 
 Nitroreductases (NTR) play an important role in catalyzing the reduction of 
nitroaromatic compounds, which are wildly distributed in the environment. 
Nitroreductase is a flavoenzyme bound with flavin mononucleotide (FMN) cofactor and a 
homodimer of 24 kDA subunits expressed in Escherichia coli. It acts via a substituted 
enzyme mechanism, whereby the bound FMN is first reduced by nicotinamide adenine 
dinucleotide phosphate (NAD(P)H) and the NAD(P)+ produced dissociates. In the second 
step, various substrates can bind to the enzyme and be reduced, in turn, by FMN. In the 
case of nitroaromatic compounds, nitroreductase catalyzes the reduction of a nitro group 
to hydroxylamine, which is subsequently converted to an amine in the presence of 
NAD(P)H. The large electronic change resulting from the conversion of the electron-
withdrawing nitro group to the electron-donating hydroxylamino group provides an 
effective ‘switch’ mechanism for the activation of an inert compound and the subsequent 
release of the active form of the agent. Based on this switch mechanism, various prodrugs 
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or switchable imaging probes have been designed with nitro groups as substrates to be 
triggered upon reduction by NTR.  
 According to previously reported NTR-catalyzed reactions, aromatic substrates 
show relatively high reactivity with NTR caused by hydrogen bonding, π−π stacking 
interaction, hydrophobic effect, and etc. The nitro groups in substrates can be reduced 
first to a nitroso group, then a hydroxylamine group, and ultimately to an amino group. In 
addition, the electron withdrawing group induces an electron-transfer process, quenching 
the fluorescence emission of a substrate, and the reduction of nitro groups by NTR leads 
to a change in fluorescence intensity. These fundamental concepts underpin an important 
strategy in the design of fluorescent probes for NTR detection and NTR activatable 
prodrugs. 
 
2.3.1. Nitroreductase activatable prodrugs and sensors 
 The first identified NTR prodrug was 2,4-dinitrobenzamide, CB1954 that is also 
known as tretazicar.35 It consists of a 2,4-dinitrobenzylamide ring linked at the 5-position 
to an aziridinyl substituent. Both nitro groups were reduced by bacterial type I NTR 
generating 2- and 4-hydroxylamine metabolites which have cytotoxic activities in 
mammalian systems.36 In vitro analysis has shown not only that CB1954 functions as a 
substrate for both T. brucei and T. cruzi NTR and but also that it blocks replication of the 
mammalian forms of the parasites.36 Currently CB1954 proceeded to clinical trials in 
combination with E. coli NTR as a potential gene-directed enzyme prodrug therapy 
(GDEPT).37 A dinitrobenzamide mustard prodrug (PR-104) was also developed as an 
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NTR activatable prodrug. PR-104 is the first developed tumor hypoxia-activated 
(GDEPT independent) therapeutic agent and has advanced to multinational Phase II 
clinical trials.38 The previous study has shown that PR-104 was tolerated by humans at up 
to twenty times the maximum dose of CB1954 on a molar basis.38 Moreover, the 
activated metabolites of dinitrobenzamide mustard prodrugs possess greater potency and 
bystander effect than CB1954.39  
 
2.3.2. p-nitrobenzyl-based prodrugs and sensors 
 Thanks to its high selectivity and sensitivity, application of NTR-catalyzed 
reaction in the design of prodrug and imaging probes have attracted considerable 
attention in the drug targeting field. Among various nitroaromatic compounds, however, 
only a limited number of studies on a nitrobenzyl trigger had been carried out in the past. 
Hu et al. first synthesized an NTR activatable phosphoramide mustard prodrug using a 4-
nitrobenzyl moiety as a redox-trigger.40 While the prodrug has low cytotoxicity in the 
absence of NTR, it showed 167,500× selective cytotoxicity toward nitroreductase-
expressing V79 cells with an IC50 of 0.4 nM.40 It suggested that 4-nitrobenzyl 
phosphoramide mustard is about 100× more active and 27× more selective than CB1954, 
indicating that a nitrobenzyl functionality is a highly selective trigger to NTR. To explore 
nitrocompound structure–activity relationships as substrates of NTR, Hu et al. have also 
synthesized a series of nitrobenzyl phosphoramide mustards.41 The results implied that a 
nitrobenzyl based prodrug offers the best enzyme activity and antiproliferative effect 
against both mammalian and trypanosomatid cells. Hu’s group has also applied a 
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nitrobenzyl group in the design of α-difluoromethylornithine (DFMO or Eflornithine) 
prodrug.42 Moreover, Charkrapani’s group has synthesized a nitrobenzyl based 
diazeniumdiolate prodrug43. Cell viability assays for DFMO prodrug and 
diazeniumdiolate prodrug have revealed that cytotoxic effects towards cancer cell lines is 
significantly enhanced in the presence of NTR. 
 
Scheme 1.2 Chemical reduction of nitrobenzyl trigger based redox-sensitive prodrug. 
 In addition to the aforementioned nitrobenzyl trigger based prodrugs, various 
selective imaging probes possessing a nitrobenzyl moiety have also been developed 
during the past several years. Cui et al. have synthesized an NTR-activatable fluorescent 
probe using a nitrobenzyl trigger and naphothalimide in 2011.44 The spectroscopic 
evaluation using reducing agents including dithiothreitol, glutathione, cysteine, 
homocysteine, NADPH and NTR verified that the probe was feasible to be reduced to 
release fluorescence at 550 nm. Even though a nitrobenzyl trigger weakens an 
intramolecular chare transfer of fluorophore, the nitrobenzyl trigger conjugated probe 
emitted fluorescence at 475 nm and at 550 nm, before and after reduction, which works 
in the relatively high energy region (400-650 nm) of the electromagnetic spectrum. To 
minimize biological auto-fluorescence, a NTR-activatable sensor with a fluorescence 
emission wavelength in the NIR region was recently developed by Shi et al.45 Cyanine 
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dyes were selected as a fluorophore with signals observed in the NIR region (>700 nm) 
and the introduction of sulfonate groups to Shi’s dyes enable the sensor to improve water 
solubility and prevent the aggregation of cyanate dye. It was demonstrated that the 
nitrobenzyl trigger caged sensor did not emit significant fluorescence but strong NIR 
emission at 708 nm in the presence of NTR. However, the antibacterial activity of this 
sensor has not been tested. Despite the previous extensive investigation about the use of a 
nitrobenzyl redox trigger for NTR activatable materials, such triggers have not been 
applied for the development of bifunctional compounds, which can serve as a tool for 
selective imaging and therapy.  
 
1.3. Organization of the dissertation 
 
 Chapter 2 discusses a QPA trigger based redox-responsive polymer for potential 
application in a tumor targeted drug delivery system. The synthesized polymers were 
utilized to prepare hydrophobic drug loaded nanoparticles. Redox-triggered drug release 
of nanoparticles was evaluated using sodium dithionite and their potential application in 
the development of tumor targeted drug delivery system was delineated as well.  
 
 Chapter 3 includes a redox-responsive amphiphilic polymer comprising a QPA 
redox trigger. Coupling of mPEG to a hydrophobic redox-responsive polymer provided 
the amphiphilic polymer with its self-assembling capability to incorporate hydrophobic 
drug into the core of micelles. The dimensional and chemical structural changes 
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occurring to the micelles in the presence of a redox chemical were characterized to verify 
if the drug releases in a redox-triggered manner. In vitro drug release kinetics and 
cytotoxicity of micelles were also discussed.  
 
 Chapter 4 elaborates the synthesis and characterization of a nitrobenzyl redox 
trigger caged NTR imaging probe. Selective uncaging of the probe via nitro reduction 
was evaluated with live E. coli. for imaging. A potential therapeutic application of the 
compound in photodynamic therapy was also addressed.  
 
 Last, in Chapter 5, we summarize the dissertation research work consisting of 
those two materials prepared from redox triggers and discuss their challenges and future 
research directions. 
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CHAPTER 2  
REDOX-RESPONSIVE PLYMERIC NANOPARTICLES FOR DRUG DELIVERY  
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ABSTRACT 
 
 Bioresponsive polymeric nanoparticles have been extensively pursued for the 
development of tumor-targeted drug delivery. Novel redox-sensitive polymeric 
nanoparticles were prepared from a synthesized monomer containing trimethyl-locked 
quinone propionic acid as a redox trigger. A hydrophobic cancer drug, paclitaxel, was 
incorporated into the redox-responsive polymeric nanoparticles prepared from the 
synthesize polymers. The particle size of nanoparticles was determined to be 180 nm (PD 
= 0.138) by dynamic light scattering. The effect of redox stress on the nanoparticles was 
evaluated with a chemical reductant, sodium dithionite demonstrating that the 
nanoparticles released >80% of paclitaxel over 24 h at a simulated redox-state compared 
to 26.5% to 41.2% release from the control. Cell viability studies revealed that the 
polymer was non-toxic and the nanoparticles could release paclitaxel to suppress breast 
cancer cell growth.   
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2.1. INTRODUCTION 
Cancer has been a major cause of mortality across the world.46 Tremendous 
efforts have already been made to improve cancer therapy, including chemotherapy, in 
conjunction with nanotechnology as well as bioimaging.47 Potent anticancer therapeutic 
agents are generally non-selective and thus affect normal cells, leading to severe side 
effects. Targeted drug delivery systems have been considered as a promising tool to 
minimize the toxicity by distributing the cytotoxic drugs favorably to tumor sites in the 
body. In particular, abnormal leaky tumor vasculatures and deficiency of lymphatic 
drainage in tumor enable nanotechnology-based targeted drug delivery to favorably 
accumulate cancer therapeutics in solid tumor while lessening their toxicity to normal 
tissues.48 For selective drug release in tumor sites, stimuli-responsive polymer-based drug 
delivery systems have been extensively explored.1 The bioresponsive delivery systems 
can undergo conformational or physiochemical property changes and release 
incorporated drugs in response to the signals stemming from tumor microenvironments 
such as acidic pH2, altered oxidation-reduction (redox)3, over-expressed enzymes4 and 
hyperthermia5.  
  Since redox changes associated with tumor hypoxia have been identified as a 
viable biomarker for tumor progression and cancer drug resistance, reductive enzymes 
overexpressed in tumor microenvironments, such as DT-Diaphorase (EC 1.6.99.2)7, 
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provide an important methodology for selective tumor targeting. Various bioreductive 
prodrugs that can be activated by the reductive enzymes specifically in hypoxic tumor 
microenvironments have been reported and some of them are currently under clinical 
trials.8 As demonstrated from aniline mustard protected with a bioreductive protecting 
group, drug activation under hypoxia, tested on T47D cells, resulted in cytotoxicity.9a 
However, the prodrug approach can be complicated with ubiquitous expression of various 
reductive enzymes in normal cells.10 Even though redox-triggered liposomes that release 
the incorporated molecule upon chemical reduction have been studied already,11e the 
delivery platform based on the redox-sensitive polymeric nanoparticles have not been 
conceived yet for targeted drug delivery applications. The approach with polymeric 
nanoparticles to target hypoxic solid tumors would have advantages over the bioreductive 
prodrugs and liposomes. They can be easily modified with the ligands that selectively 
interact with the molecules expressed on cancer cells to achieve active targeting to cancer 
cells. In addition, polymeric nanoparticles cannot be limited by the physicochemical 
properties of the drugs to be loaded. Unlike to liposomes, polymeric nanoparticles can 
easily adopt various cytotoxic drugs, either hydrophobic or hydrophilic for drug 
targeting. Furthermore, the polymeric nanoparticles can be modulated for increased 
circulation time and favorable accumulation in tumor.12 
 DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO1), EC 1.6.99.2) is an 
obligate two-electron cytosolic reductase which reduces and detoxifies quinones and their 
derivatives as a part of an electrophilic and/or oxidative stress-induced cellular defense 
mechanism. DT-diaphorase is overexpressed in many cancerous tissues compared to 
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surrounding normal tissues.49 In the case of non-small-cell-lung (NSCLC) tumors, a DT-
diaphorase activity determined using 2,6-dichlorophenolindophenol was found to be 123 
nmol min-1 mg-1 compared to 6.4 nmol min-1 mg-1 in normal cells, a 20-fold increase. 
Since DT-diaphorase was known to activate quinone-bearing anticancer drugs, various 
quinone derivatives have been studied as a viable component of bioreductive cancer 
chemotherapeutics.50 In addition, quinone-based bioreductive prodrugs which release 
active cytotoxic drugs have been designed to selectively target cancer cells by 
overexpressed DT-diaphorase. Interestingly, trimethyl-locked quinone propionic acid 
(QPA) has been known to readily undergo intramolecular cyclization by DT-diaphorase-
mediated two-electron reduction and release a lactone. Because of this unique property of 
the QPA group, it has been extensively applied for cancer research as an efficient redox 
trigger.51  
 Redox-triggered bioimaging probes consisting of QPA have been synthesized to 
liberate fluorescent indicators after DT-diaphorase-mediated activation.52 Furthermore, 
QPA has been applied for the synthesis of bioreductive prodrugs based on aniline 
mustard53 and oxindoles54 for selective tumor targeting. Even redox-triggered liposomes 
that electrochemically release chemicals have been designed with the QPA chemistry.52a  
Chemical reduction-induced shedding of QPA from the liposome surface resulted in the 
structural change of the supramolecular assemblies, which later destabilized the redox-
sensitive liposomes to electrochemically release a hydrophilic fluorescent dye, calcein. 
However, the QPA-based redox chemistry has never been applied for a polymeric drug 
delivery system thus far. The approach to use QPA-based redox-sensitive polymeric 
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nanoparticles is advantageous over the QPA-based prodrugs or liposomes to target the 
redox stress in solid tumors. Polymeric nanoparticles can be easily modified with the 
ligands that selectively interact with the molecules expressed on cancer cells to achieve 
active targeting. In addition, the nanoparticles may be more flexible than the above-
mentioned liposome for the formulation of hydrophobic cancer drugs since they may 
disrupt exquisitely balanced non-covalent interactions of QPA at the liposome surface. 
Furthermore, the nanoparticles can easily achieve prolonged circulation in blood and 
preferred accumulation in tumor by poly(ethylene glycol) (PEG) coupling. 
 
 
Scheme 2.1. Chemical reduction of the redox-sensitive polymers based on trimethyl-
locked benzoquinone. 
 In this chapter, we describe a novel redox-sensitive polymer containing amino 
groups protected with a QPA redox trigger, which is able to respond to the redox 
variation with polymer property changes. The polymer is designed to release a lactone 
from QPA and unmask free amino groups via the two-electron reduction mediated by 
chemical agents, such as sodium dithionite (Na2S2O4). As a result, the reduced polymer 
would have enhanced water solubility at neutral pH upon protonation of free amino 
groups. Thus, nanoparticles prepared with the redox-sensitive polymer would be able to 
25 
 
release incorporated drugs upon polymer hydration in response to redox changes 
(Scheme 2.1). We first synthesize the monomers with QPA trigger to obtain redox-
sensitive polymer. The polymers were utilized for the preparation of PTX-loaded 
nanoparticles. The nanoparticles were evaluated for redox-triggered drug release under a 
simulated redox state. In vitro cytotoxicity of nanoparticles was determined in human 
breast tumor T47D and MDA-MB-231 cells to determine cancer cell-mediated drug 
release. 
 
 
2.2. EXPERIMENTAL 
2.2.1.Materials 
 Methanesulfonic acid, 2,3,5-trimethyl hydroquinone, methyl β,β-
dimethylacrylate, 2-amino-1,3-propanediol, adipoyl chloride and glutaryl chloride were 
obtained from Alfa Aesar (Ward Hill, MA). Adipoyl chloride and glutaryl chloride were 
distilled under reduced pressure before the reaction. Paclitaxel (PTX) was purchased 
from LC Laboratories® (Woburn, MA). Polyvinyl alcohol (PVA; Mw 30,000 - 70,000) 
was obtained from Sigma-Aldrich (St. Louis, MO).  All other chemicals purchased from 
Fisher Scientific (Pittsburg, PA) were used as received.  
 
2.2.2. Computational analysis  
Polymer Construction 
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QPA-based redox-sensitive polyester structures were constructed by combinations 
between N-(1,3-dihydroxypropan-2-yl)-3-methyl-3-(2,4,5-trimethyl-3,6-dioxocyclohexa-
1,4-dien-1-yl) (monomer 1 in scheme 2.2, QPAMN) and  two dicarboxylic acids, glutaric 
acid and adipic acid. According to the nature of the repeating units, the polymers were 
constructed head-to-tail in 3D using the polymer builder tool of Molecular Operating 
Environment (MOE) software package (ver. 2011.10, Chemical Computing Group, 
Montreal, Canada). We considered the three possible degrees of reduction –non-reduced, 
partially reduced and reduced– of QPA groups because of their potential effects on 
polymer solubility and drug release. Polymer chains of two molecular weights ~3000 and 
~5000 Daltons were sketched. 
 
Calculation of logP 
The logP calculations used the weighted-method of ChemAxon suite 
(MarvinSketch 5.6.0.1, 2011, www.chemaxon.com), which is a combination of three 
algorithms, VG method (logP calculation according to various atom types)55, KLOP 
method (group contribution approach)56 and PHYSPROP (based on a logP database).57 
The logP calculated in this way is the arithmetic average of the three methods.  
 
2.2.3. Synthesis of monomer 
 NHS-activated benzoquinone compound 4, NHS-QPA (scheme 2.2) was 
synthesized as reported previously.9a To a mixture of 2-amino-1,3-propanediol (1.639 g, 
18 mmol) and triethyl amine (5 mL) in isopropanol (100 mL), the synthesized compound 
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4 (4.168 g, 12 mmol) in THF (50 mL) was added dropwise at room temperature. After 
being stirred overnight at room temperature, the mixture was collected and concentrated 
under reduced pressure. The crude compound was washed with NaHCO3 three times and 
extracted by ethyl acetate (50 mL × 3), then dried over by sodium sulfate. The reductive 
monomer 1 (yellow crystalline) was purified by recrystallization in ethyl acetate with an 
isolated yields of 61.3% (2.379 g). NMR spectra were recorded on a Bruker 
UltrashieldTM 400 PLUS at 400 and 100 MHz for 1H and 13C, respectively. The residual 
solvent peak (δ = 2.50 or 7.24 for DMSO-d6 or CDCl3, respectively) were used as the 
solvent residual references for 1H NMR spectra, and chemical shifts of the solvent peaks 
(δ = 39.52 or 77.00 for DMSO-d6 or CDCl3, respectively) were used as the reference for 
13C NMR spectra. 
 
Monomer 1, yellow crystal; mp 161–162 °C (from EtOAc) , 1H NMR (400 MHz, 
DMSO-d6) δ = 7.54 (d, J = 8.3 Hz, 1H), 4.56 (t, J = 5.5 Hz, 2H), 3.60 (dt, J = 8.2, 5.6 Hz, 
1H),3.32 (m, 4H), 2.71 (s, 2H), 2.01 (s, 3H), 1.90 (s, 3H), 1.87 (s, 3H), 1.32 (s, 6H); 13C 
NMR (101 MHz, DMSO-d6) δ = 190.20, 186.85, 171.31, 154.94, 144.03, 136.07, 135.37, 
60.13, 52.70, 47.58, 37.69, 28.06, 13.69, 12.77, 11.70; IR (neat, cm-1) 1528, 1600, 1638, 
3333; Found: C, 63.20; H, 7.71. Calcd for C17H25O5: C, 63.14; H, 7.79.  
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Scheme 2.2. Synthetic reactions for a trimethyl-lock quinone-based redox-sensitive 
monomer. 
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Figure 2.1. 1H and 13C NMR spectra of monomer 1 in DMSO-d6. 
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Scheme 2.3. Schematic synthetic reactions for redox-sensitive polymer with QPA and 
mechanism under reduction. 
 
2.2.4. Synthesis of polymer 
 Freshly distilled glutaryl chloride (242.7 mg, 1.44 mmol) was diluted ten times 
with dry THF and slowly added to the solution of monomer, QPAMN (464.3 mg, 1.44 
mmol) in pyridine at room temperature (Scheme 2.3.). The reaction was further carried 
on at room temperature overnight. After being poured into an excess amount of ethanol 
and mixed for 6 hours, it was extracted with deionized (DI) water and later with CH2Cl2. 
The collected organic phase was concentrated by a rotary evaporator and precipitated into 
cold diethyl ether to obtain the crude product, (3a, 470.8 mg). The adipic acid based 
polymer (3b, 571.4 mg) was synthesized with the same procedure shown above using 1.3 
mL of pyridine monomer 1 (517.5 mg, 1.60 mmol) and dried adipoyl chloride (292.6 mg, 
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1.60 mmol). The structures of the synthesized polymers, 3a and 3b, were elucidated by 
1H-NMR spectra using a Bruker Avance 400 MHz spectrometer. The molecular weight 
and polydispersity index (PDI) of the synthesized polymers were determined with a 
Waters gel permeation chromatography (GPC) system (Waters, Milford, MA). GPC 
instrument is equipped with a binary pump (Waters 1525), a refractive index detector 
(Waters 2414), and a Styragel HR4E column (300 × 7.8 mm ID, 5 µm particle size). The 
measurement of the molecular weight was performed using HPLC grade THF as a mobile 
phase at a flow rate of 1.0 mL min-1 at 25 °C. The molecular weight of the synthesized 
polymers was determined with the calibration curve obtained using polystyrene standards 
(600-50,000 Da). Under these conditions, retention times of 3a and 3b were 8.559 min 
and 8.609 min, respectively.  
 
Polymer 3a; 1H-NMR (400 MHz, CDCl3): δ 6.32 (1H, s), 4.38 (1H, s), 4.12 (2H, s), 4.06 
(2H, s), 2.85 (2H, s), 2.38 (4H, t), 2.13 (3H, s), 1.95 (8H, m), 1.39 (6H, s). 
Polymer 3b; 1H-NMR (400 MHz, CDCl3): δ 6.30 (1H, s), 4.37 (1H, s), 4.12 (2H, s), 4.06 
(2H, s), 2.83 (2H, s), 2.36 (4H, t), 2.11 (3H, s), 1.95 (10H, m), 1.39 (6H, s). 
 
2.2.5. Preparation of blank and PTX-loaded nanoparticles 
 The blank and PTX-loaded nanoparticles (NPs) were prepared by an single 
emulsion method.58 NPs-3a from polymer 3a and NPs-3b from polymer 3b were obtained 
through the same procedure. For preparation of PTX-loaded NPs, 40 mg of the 
synthesized redox-responsive polymer and 4 mg of PTX were dissolved in 2 mL of 
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CH2Cl2. This organic phase was slowly added to 18 mL of phosphate-buffered saline 
(PBS, pH 7.4) containing 0.7% of PVA mixing under magnetic stirring. The mixture was 
emulsified for 1 min in an ice bath by a probe sonicator (Qsonica, LCC. XL-2000, 
Newtown, CT). The emulsion was stirred overnight at room temperature to evaporate 
CH2Cl2. Aggregated NPs were filtered off with a 0.45 µm filter. The NPs were collected 
from the filtered solution by centrifugation (VWR TM Galaxy 14D, 6,000 rpm, 15 min). 
The NPs were washed twice with PBS, 20 mL each time, and later with 20 mL of DI 
water to remove emulsifier. The produced suspension was lyophilized with the addition 
of 20 mg of mannitol to obtain fine powder of NPs. To prepare blank NPs, the above-
mentioned procedures were employed except for leaving out PTX.  
 
2.2.6. Characterization of blank and PTX-loaded NPs 
 The amount of PTX loaded in NPs was determined by dissolving a known weight 
(1.05 mg) of freeze-dried drug loaded NPs into 1 mL of acetonitrile and was analyzed via 
HPLC. The HPLC system is equipped with a Luna C18(2) chromatographic column 
(Phenomenex, 150 x 4.6 mm, 5 µm), a binary pump (Waters 1525), and an auto-sampler 
(Water 717). The mobile phase, a mixture of acetonitrile and water at 55/45% v/v, was 
used at a flow rate of 1 mL min-1 after injecting a 20 µL sample.59 PTX was detected at a 
retention time of 4.9 min using a UV detector (Water 2487) at 227 nm. The concentration 
of released PTX was calculated using the calibration curve obtained from different 
concentrations of PTX standard solutions in acetonitrile. The percentage of PTX 
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incorporated into NPs was calculated by dividing the amount of incorporated PTX with 
the initial PTX amount and multiplied by 100. 
 The size distribution and Z-average diameter of the NPs were determined by 
dynamic light scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). NP suspensions were diluted to a concentration of 1.25 g NP in 1 
mL of DI water. NP sizes were measured before freeze-drying and after reconstituting the 
NPs freeze-dried in the presence of mannitol in order to test the protective effect of 
mannitol during drying NPs.  
 For scanning electron microscope (SEM) analysis, NPs were reconstituted at a 
concentration of 1 mg mL-1 in DI water and homogeneously suspended by a 5 min 
sonication. A 50 µL aliquot of the reconstituted sample was mounted on an aluminum 
plate and dried. Then, the sample was sputter coated with gold and palladium. Quanta 
FEG 650 (FEI) at an accelerating voltage of 10 or 15 kV was used to image NPs.60 The 
polymeric nanoparticles were also characterized by transmission electron microscopy 
(TEM) using a Tecnai T12 microscope (FEI, Hillsboro, OR) operated at 80 kV. Each 
sample was sonicated for 5 minutes before being mounted on a carbon coated Formvar 
cooper grid (400 mesh) and dried for 3 minutes.  After wicking away excess solution and 
air drying for 1 minute, samples were then negatively stained with uranyl acetate (2% 
w/v) for 30 seconds prior to TEM imaging. 
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2.2.7. In vitro drug release studies 
 In vitro PTX release from the prepared NPs was conducted using Na2S2O4 as a 
reducing agent. An amount of PTX-loaded NPs-3b containing 10 µg of PTX was 
suspended in 3 mL of PBS buffer (pH 7.4) containing 0.8 M of sodium salicylic acid. The 
drug release was initiated by an addition of Na2S2O4 to the NP suspension. A 200-fold 
molar excess of the reducing agent to QPA groups in the polymer was employed. Then, 
the mixture was incubated in a shaking water bath (100 rpm) at 37 °C for 24 hours. At 
designated times, a 150 µL aliquot of the NP sample was withdrawn from a vial after 
spinning down the NPs and an equal volume of fresh reducing medium was added and 
stirred into the NP solution. Samples were diluted with 150 µL of acetonitrile and the 
supernatant samples obtained with centrifugation (13,000 rpm, 3 min) were injected into 
the HPLC for analysis. The amounts of released PTX in the collected samples were 
determined by the same HPLC method as described in 2.5 except for external standard. 
The calibration curve was obtained from different concentrations of PTX standard 
solutions in 50% (v/v) aqueous acetonitrile. For the quantitative determination of lactone 
reduced from QPA groups, synthesized lactone was applied as external standard for 
HPLC analysis as previously reported.57  The retention times of released lactone and PTX 
were 4.98 min and 6.68 min, respectively, at 227 nm with an UV detector. 
 The drug release from NPs in cell media was also studied in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with/without 5% fetal bovine serum (FBS). 
PTX-loaded NPs-3b (0.72 mg) were suspended into 1 mL of cell media incubating at 37 
°C. At designated time point over 48 hours, 150 µL NP solution was withdrawn from the 
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system and centrifuged at 10,000 rpm for 5 min to spin down NPs. Aliquots of 110 µL 
NP solution from supernatant media were mixed to the same amount of acetonitrile (110 
µL) to remove protein precipitate. The remaining 40 µL solution including precipitated 
NPs was suspended with the same volume of fresh media and the suspension was added 
to the system to keep constant volume.  After completing the collecting samples, the NP 
solution was mixed with the same volume of acetonitrile (1 mL) to measure the amount 
of PTX remaining in the NPs. To determine the amount of PTX, all collected samples 
were centrifuged to remove protein precipitate for the preparation of samples and HPLC 
method was used in the same manner as for the measurement of the amount of drug 
incapsulated in NPs. 
 
2.2.8. Cell viability assay 
 Human breast tumor T47D and MDA-MB-231 cells obtained (ATCC, Manassas, 
VA) were grown in DMEM/F12 medium containing 2.5 mM L-glutamine (Mediatech), 
supplemented with fetal bovine serum (FBS, 10% v/v final concentration, Hyclone), 
penicillin G (sodium salt, 50 units mL-1) and streptomycin sulfate (50 µg mL-1) 
(BioWhittaker). Exponentially grown cells were plated at the density of 30,000 cells per 
well into 96-well plates in a volume of 100 µL culture media and incubated at 37 °C in a 
humidified environment (95% air, 5% CO2), as previously described.61 PTX was 
dissolved in DMSO to obtain a 20 µM stock solution. PTX loaded NPs and blank NPs 
were prepared fresh as 100 µM stock solutions in PBS (pH 7.4). After compound 
treatment at the specified concentrations for 48 h, the cells were further incubated and 
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cell viability was determined by the sulforhodamine B (SRB) method.62 Optical density 
(OD) was measured at 490 nm with background absorption at 630 nm. Data were 
normalized to the untreated control and presented as ‘% of control,’ using the formula. 
   Cell viability [% of Control] = (ODtreated/ODcontrol) × 100                         
 
2.2.9. Statistical analysis 
 Experimental measurements were triplicated for each sample. The results are 
presented as mean ± standard deviation. The statistical analysis of experimental data 
utilized the student’s t-test and statistical significance was considered for P-values < 0.05. 
 
 
2.3. RESULTS AND DISCUSSION 
2.3.1. Computational analysis and polymer synthesis  
Molecular dynamics and molecular docking have been widely used in the process 
of drug development as means to predict and rationalize the design of drug delivery 
systems.63 Theoretical calculation of logP provides rapid evaluation of lipophilicity and 
cellular penetration, which is widely used as a rational tool in the drug design process. 
Two polymers were constructed by combinations of previously synthesized QPAMN and 
dicarboxylic acids, glutaric acid and adipic acid. The main reason to select the two di-
carboxylic acids was that NPs from the adipic acid-based redox-sensitive polymer have 
demonstrated redox-triggered content release by solubility reversal upon polymer 
reduction.57 Two polymer molecular weights, 3000 and 5000 Daltons, were considered to 
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test lipophilicities using ChemAxon. The logP calculated from the arithmetic average of 
the three ChemAxon logP methods including VG, KLOP and PHYSPROP showed the 
lower values in the reduced forms. As shown in Table 2.1., fully reduced polymer with 
molecular weight of < 5000 Da showed the decrease of logP values of 3a and 3b from 
27.81 to -6.29 and from 32.46 to -0.39, respectively. The logP values of polymer with 
MW < 3000 Da were similar and were lowered from 18.87 and 19.72 to -4.01 and -0.39 
with the increase in reduction of polymers 3a and 3b, respectively. Reduction-dependent 
logP change in the polymers is probably due to the exposure of hydrophilic amine group 
upon removal of QPA. Especially, exposed primary amine groups would further lower 
polymer logP by protonation.  
 
2.3.2. Synthesis of monomer and polymers 
 Redox-sensitive polymer was designed from the monomer with a QPA trigger. 
Initially, benzoquinone carboxylic acid (β,β,2,4,5-pentamethyl-3,6-dioxo-1,4-
Table 2.1. Calculated logP values of QPA-based redox-responsive polymers at 
different degrees of reduction. Two polymer molecular weights, 3000 Da and 5000 
Da, were chosen for comparison. 
 MW ~5000 MW ~3000 
  Non reduced 
Partially 
reduced 
Fully 
reduced 
Non 
reduced 
Partially 
reduced 
Fully 
reduced 
Polymer 3a 27.81 10.30 -6.29 18.87 7.21 -4.01 
Polymer 3b 32.46 16.27 -0.55 19.72 10.53 -0.39 
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cyclohexadiene-1-propanoic acid) activated with N-hydroxylsuccimide was synthesized 
according to the previous report.11a The activated compound was coupled with serinol (2-
amino-1,3-propanediol) as a redox-sensitive diol monomer to yield serinol-derived 
polyester upon esterification with diacyl chloride. Serinol was selected for 
polymerization because of proven biocompatibility of the serinol-derived polyesters.13 A 
coupling reaction between trimethyl-lock benzoquinone succinimidyl ester and serinol in 
a basic condition, successfully yielded diol monomer containing a QPA (QPAMN), 
which was confirmed by 1H and 13C NMR spectroscopy and elemental analysis. The 
polymers 3a and 3b, designed for redox-triggered NPs were synthesized as illustrated in 
Scheme 2.3. The molar ratio of QPAMN to diacyl chlorides was 1.0 to achieve the 
highest possible polymer molecular weight which has reached 9,000 Da previously. 
Polymer 3a synthesis yielded orange-yellow powders with a number-average molecular 
weight (Mn) of 6980 Da (PDI = 1.5). Throughout this study, polymer synthesis has been 
reproducible to show a very narrow molecular weight variation with a standard deviation 
within 3% of polymer molecular weight. The proton NMR of polymer 3a in CDCl3 
showed all the characteristic peaks and splitting in Figure 2.2.. The chemical shift of -
CH2-OH protons in QPAMN appearing at 3.32 ppm moved downfield to δ = 4.12 ppm 
and 4.06 ppm, indicating ester formation upon polymerization. Furthermore, 
characteristic methyl protons in QPAMN appearing at 1.41, 2.13 and 2.33 ppm were also 
found in the polymer NMR spectrum, which showed the incorporation of the intact QPA 
pendant group in the polymer backbone. Compared to the peak shapes in monomers, 
corresponding peaks in the polymer were also broadened after the polymerization as 
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expected. The integration ratios of proton peaks on 1H-NMR spectrum were consistent 
with the theoretical ratios of proton numbers in the polymer (Figure 2.3.)  
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Figure 2.2. 1H NMR spectrum of the redox-responsive polymer 3a. 
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Figure 2.3. 1H NMR spectrum of the redox-responsive polymer 3b. 
  
 
2.3.3. Preparation of redox-responsive NPs 
Redox-responsive NPs were prepared in the presence or absence of PTX from the 
synthesized polymers. An emulsion method using PVA was employed to obtain NPs with 
controlled particle sizes. Although particles smaller than 500 nm can be passively 
accumulated in tumor by the enhanced permeability and retention (EPR) effect, NPs with 
particle sizes are less than 200 nm are generally considered as ideal for targeted drug 
delivery.64 Emulsifying hydrophobic polymers and subsequent solvent evaporation have 
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frequently yielded NPs suitable for tumor-targeted drug delivery.65 The mean size of 
NPs-3a was determined to be 246.0 nm (PDI = 0.12) and 238.8 nm (PDI = 0.15), for the 
blank NPs and PTX-loaded NPs, respectively, as summarized in Table 2.2. It was found 
that the use of surfactants for the preparation of redox-responsive NPs affected particle 
size. Tween 80 and Pluronic F68 indeed resulted in particle sizes ranging from 400 nm to 
830 nm (data not shown). The nonionic stabilizers might differently affect the stability of 
the oil-in-water emulsions of the redox-responsive polymers. Droplet sizes of the 
emulsions could be an important factor for the size of final hardened polymer NPs. The 
sizes of our redox-responsive NPs were comparable to the particle sizes obtained with 
poly(D,L-lactide-co-glycolid) (PLGA).66 The size of PLGA (MW 75,000-120.000) NPs 
prepared with Pluronic F68 was 461 ± 10 nm, which was larger than the 284 ± 6 nm 
obtained with PVA.66 This result indicated that PVA in CH2Cl2 could decrease interfacial 
tension more than Pluronic F68 did and, thus, lead to smaller particles size. The increase 
in size of obtained NPs was observed due to the aggregation of NPs when using Tween 
80 and similar observations were also reported on the formation of poly(D,L-lactic acid) 
NPs emulsified with Tween 80.66 
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Figure 2.4. Size distribution of blank nanoparticles (A) and paclitaxel incorporated 
nanoparticles (B) by dynamic scattering method (DLS) 
  
 PTX loading into NPs-3a was determined to be 45% (w/w) as summarized in 
Table 2.3. However, NPs-3b resulted in an enhanced drug loading of 77% (w/w). It 
looked as though an additional carbon in the polymer repeating unit in polymer 3b might 
be attributed to the difference in drug loading in two kinds of NPs. As previously 
observed, drug loading into polymer particles is closely related to drug solubility in the 
polymer. It is speculated that polymer 3b may have greater miscibility with PTX than 
Z-­‐average	  size:	  267nm	   
(PDI:	  0.214) 
(A) 
(B)
) 
Z-­‐average	  size:	  180nm	   
(PDI:	  0.138) 
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polymer 3a because of greater hydrophobicity as predicted by theoretical logP 
calculations (Table 2.1.).  
 Aggregation of hydrophobic NPs during freeze drying has commonly been 
observed.67 Carbohydrate stabilizers such as sucrose, lactose, glucose, sorbitol, and 
mannitol have been routinely employed to prevent the product from undergoing the stress 
that could destabilize colloidal suspension, which is generated during the freeze drying 
process.68 For the freeze-drying of redox-sensitive polymer NPs prepared from QPA-
based polymer, mannitol was added to minimize particle aggregation and improve the 
handling properties of the dried NPs. It should be noted that mannitol has been widely 
used as a cryoprotectant in the formulations of biotechnology products which are 
currently in the market.69 It has also been known that mannitol tends to crystallize during 
freeze-drying process resulting in powdery and dry products, which usually improves 
handling property.70 The protective effect of mannitol during freeze drying was examined 
by particle size measurements before and after nanoparticle drying. The size of redox-
responsive NPs-3b before drying was determined to be 220.60 ± 21.56 nm (PDI = 0.16 ± 
0.07). Nanoparticle size slightly increased to 269.83 ± 21.56 nm (PDI = 0.24 ± 0.05) after 
reconstitution of the dried NPs into water (summarized in Table 2.2). This slight particle 
size increase may be due to hydration of NPs. The redox-responsive polymer NPs seemed 
to be aggregated by inter-particular hydrophobic interactions during freeze drying 
without mannitol.71 It appears that nanoparticle aggregation was prevented by the 
presence of mannitol which can hold water and fill spaces between NPs during the drying 
process. Drug loading did not noticeably diminish the protective role of mannitol to 
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hinder particle aggregation. In the case of PTX-loaded NPs-3b, particle size was 
marginally increased from 256.47 ± 9.55 nm (PDI = 0.08 ± 0.03) to 293.17 ± 13.21 (PDI 
= 0.17 ± 0.06) for wet NPs before drying and reconstituted particles after freeze-drying, 
respectively, in the presence of mannitol (Table 2.2). In addition, lyophilized NPs have 
maintained their stability over an eight week period (summarized in Figure 2.5). 
Reconstituted PTX-loaded NPs-3b have shown a modest particle size increase from 293.2 
nm to 346.4 nm over an eight week incubation at 37 °C (Figure 2.5). Interestingly, a 
noticeable change in particle size modification was observed with blank NPs, wherein the 
size of NPs increased from 269.8 nm to 558.5 nm in 4 weeks. The particle size further 
increased to 682.8 nm in another 4 weeks. The hydrophobic drug might have contributed 
to an improved stability of PTX-loaded NPs. 
Table 2.2. Mean sizes of prepared redox-responsive polymer nanoparticles and drug 
loading efficiency into the nanoparticles. Mannitol was used to stabilize the particles 
during freeze-drying. Paclitaxel was used as a model drug. Data presented as mean ± 
standard deviation of three independent experiments. 
NPs 
Size (nm) Drug loading 
efficiency 
(w/w) mannitol-free 
drying with 
mannitol 
Blank NPs-3a 246.03 ± 42.58 322.07 ± 28.59   
PTX loded NPs-3a 238.8 ± 20.49 257.67 ± 43.89 45% 
Blank NPs-3b 220.60 ± 21.56 269.83 ± 26.57   
PTX loded NPs-3b 256.47 ± 9.55 293.17 ± 13.21 77% 
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Figure 2.5. Size distribution of blank NPs-3b (□) and PTX-loaded NPs-3b (■) suspended 
in DI water and incubated at 37 °C over eight weeks. Data shown as mean ± SD (n = 3). 
Other NPs prepared from gelatin, poly(D,L lactide-glycolide) and lipids have also 
demonstrated a similar mannitol-mediated protective effect with no significant particle 
size alteration after freeze drying.72 In addition, as shown in Figure 2.6., mannitol was 
well integrated with the redox-responsive NPs-3b. The morphologies of NPs with or 
without PTX loading after drying in the presence of mannitol were different from that of 
freeze-dried mannitol as confirmed by SEM images. SEM images of dried mannitol 
revealed spherical particles with relatively uniformed size as well as rounded morphology 
(Figure 2.6.(C)). On the other hand, the microscopic images of dry NPs (Figure. 2.6.(A) 
and (B)) showed that mannitol has been integrated well with polymer NPs by showing 
chunks rather than segregated mannitol spheres. Mannitol integrated with the NPs might 
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be distributed between particles as a space filler or as a coat on their surface, which 
prevents inter-particular hydrophobic interactions between NPs. 
 
Figure 2.6. Scanning electron microscopy images of freezing dried nanoparticles 
prepared with mannitol (A) PTX-loaded NPs-3b and (B) Blank NPs-3b, and (C) Freeze-
dried mannitol. 
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Figure 2.7. The TEM images of blank nanoparticles (left) and paclitaxel incorporated 
polymeric nanoparticles (right) 
 
2.3.4. In vitro paclitaxel release  
 The effect of redox stress on the nanoparticles was tested with a chemical 
reductant, sodium dithionite (Na2S2O4). It was expected that sodium dithionite would 
reduce QPA to leave free amine groups on the polymer, which would result in physico-
chemical changes in nanoparticles that would induce nanoparticle swelling or 
dissolution at pH 7.4. Sodium dithionite-induced reduction dramatically increased the 
hydrodynamic diameter of the nanoparticles from 178 nm in a turbid solution to 29.3 µm 
in a transparent solution, a size beyond the measurable limit by the Zetasizer as shown 
in Fig. 2.8. The size changes might have resulted from the protonation of free amine 
groups in serinol of which pKa is around 9.15. 
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Figure 2.8. Change in nanoparticle size in the presence of sodium dithionite determined 
by DLS. 
 
 PTX release from the redox-responsive NPs was studied under a redox state 
simulated with a chemical reducing agent, sodium dithionite. Sodium dithionite has been 
frequently adopted in physiology experiments as a means to lower solutions’ redox 
potential (E° -0.66V at pH 7 at 0.35 nM73) and to mimic a reductive environment. Figure 
2.9.(A) shows that QPA-based redox-responsive NPs were able to release incorporated 
drug upon pendant QPA group reduction. Under a redox state simulated with sodium 
dithionite, the amounts of released PTX were significantly greater than PTX release in 
PBS (P < 0.05 for NPs-3a and NPs-3b at 15 min, P < 0.01 at 3 hours, in Figure 2.9.(A)). 
Cumulative percentage of PTX released from two different NPs was more than 80% after 
a 24 h incubation under the redox state. However, only 41.2% and 26.5% of incorporated 
PTX were released from the NPs in the absence of the reducing agent. It was interesting 
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to note that the NP from adipic acid-based redox-responsive polymer 3b showed PTX 
release comparable to that from NPs-3a.57 Lactone released from reduced QPA was 
consistent with PTX release indicating PTX release was mediated by lactone release. 
Facilitated PTX release under the redox state can be attributed to QPA reduction which 
deprotects amine groups in the polymer backbone. Free amine groups exposed upon 
intramolecular cyclization of QPA could increase polymer solubility upon protonation at 
pH 7.4, which might result in nanoparticle swelling. Theoretical calculations of 
hydrophobicity reduction upon polymer reduction, from 27.81 to -6.29 and from 32.46 to 
-0.55 for polymers 3a and 3b, respectively (Table 2.1), also led to the prediction of 
polymer solubility increasing upon polymer reduction. In addition, exposed amine groups 
might contribute to the hydrolysis of the polyester backbone in a base-catalyzed 
manner.74 As expected, NPs in the control release medium containing no reducing agent 
did not release quinone lactone at all (Figure 2.9.(B).  It is worthwhile to mention that 
NPs-3b showed lower initial PTX release than NPs-3a. The difference in burst PTX 
release from the NPs can be attributed to the polymer solubility difference. As previous 
theoretical calculations of polymer property predicted, polymer 3a is less hydrophobic 
than polymer 3b which has one more carbon in polymer repeating unit. Predicted logP 
values (Table 2.1) for non-reduced polymer 3a and 3b were 27.81 and 32.46, respectively 
at a molecular weight of 5000 Da. It seemed that more hydrophobic polymer NPs-3b 
demonstrate the lower initial burst. Considering theoretical polymer property prediction 
and experimental drug release under a simulated redox state, NPs-3b would be more 
suitable for drug delivery applications, with a low burst drug release but maximized 
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content release upon polymer reduction. However, drug release from the NPs by cancer 
cell-overexpressing redox enzymes should be further tested and confirmed before the 
implementation of the novel redox-responsive polymer NPs for tumor-targeted drug 
delivery. 
 
Figure 2.9. (A) In vitro redox-responsive release of PTX and (B) release of lactone from 
reduced QPA when incubated in the reductive media including Na2S2O4 (● and ■) and at 
control media (○, □ and x) at 37 °C from NPs-3a (● and ○) and from NPs-3b (■ and □). 
The results represent the mean ± SD (n = 3). 
 
2.3.5. In vitro cytotoxicity  
 Concentration-dependent cell cytotoxicity studies were performed to determine 
the effects of PTX–loaded redox-responsive NPs on the proliferation/viability of human 
breast tumor T47D and MDA-MB-231 cells. PTX-loaded and blank NPs-3a were used as 
positive and negative controls for the study, respectively. At the lower concentration 
range (0.01 µM or less), almost no cytotoxicity for both cell lines could be detected as 
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shown in Figure 2.10. When the concentration was at 1 µM, the cell viability of T47D 
cell line with the incubation of PTX and PTX loaded NPs were 69% and 73%, 
respectively, while the result of cytotoxicity with blank NPs showed its less toxicity as 
91% of cell viability in Figure 2.10 (A). The cell experiment for MDA-MB-231 cell line 
in Figure 2.10 (B) also showed similar cell viability, in which 48%, 50%, and 97% of cell 
viability were observed for plain drug, PTX loaded NPs, and blank NPs, respectively. 
PTX loaded NPs inhibited cell proliferation and viability to the comparable extent as that 
observed in the presence of PTX. The particle itself did not affect cell 
proliferation/viability at all concentrations tested indicating that all incorporated PTX has 
been released from NPs to limit cell growth. 
 
Figure 2.10. Effects of PTX-loaded NPs on human breast tumor cell 
proliferation/viability determined by SRB method: (A) T47D cells. (B) MDA-MB-231 
cells. Exponentially grown T47D and MDA-MB-231 cells were exposed to the different 
concentration of PTX-loaded NPs, blank NPs, and PTX for 48 h under normoxic 
condition (95% air: 5% CO2). The percentage of viable cells was normalized to values 
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obtained from untreated control under normoxia conditions, and presented as “% 
Control”. Data shown are average ± standard deviation (n = 3). 
 Aside from in vitro cellular study, in vitro drug release from the NPs was 
examined to confirm culture cancer cell-mediated drug release from NPs using serum-
free cell culture media and culture media supplemented with 5% FBS presented in Figure 
2.11. The amounts of drug released from the NPs over 48 h ranged from 12.58% to 
15.71% and from 10.89% to 14.66% in serum free DMEM and in DMEM with 5% FBS, 
respectively. In addition, the analysis of remaining NPs showed considerable amounts of 
PTX left in the NPs, indicating that FBS might contribute to drug release in part but not 
all. The amounts of drug found in the NPs were 86.05% and 53.67% in serum free 
DMEM and DMEM with 5% FBS, respectively. The reason for less drug retention in the 
presence of FBS might be the enzymes in FBS. It has been known that FBS contains a 
mixture of enzymes including esterases and proteases which are able to degrade polyester 
backbone in the QPA-based redox-responsive polymer. Proteins in FBS, 23 g L-1 of 
albumin and 38 g L-1 of total protein, may also be able to affect polymer degradation, 
nanoparticle stability or PTX protein binding.75 Indeed, PTX was reported to significantly 
bind to protein in cell culture media, which was PTX concentration dependent. PTX was 
known to result in 78.6 ± 2.7% protein binding at a concentration of 0.5 µg mL-1 in cell 
culture medium with 9% FBS and PTX binding to proteins decreased to 20.2 ± 1.4 % as 
concentration of PTX increased to 15 µg mL-1. The PTX protein binding might 
overestimate PTX release in FBS containing DMEM. However, taking cell cytotoxicity 
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results and in vitro drug release in culture media together, cultured cancer cells could 
release PTX from the redox-responsive NPs.  
 
Figure 2.11. In viro PTX release from NPs-3b in different cell culture media: serum-free 
cell culture media (○)  and the media supplemented with 5% FBS (●). Data shown as 
mean ± SD (n = 3). 
 
2.4. CONCLUSIONS 
 Novel redox-sensitive polymeric nanoparticles were prepared from a synthesized 
monomer containing quinone propionic acid as a redox sensitive group. A hydrophobic 
cancer drug, paclitaxel, was incorporated into the polymeric nanoparticles and released 
by sodium dithionite-mediated reduction in a triggered manner. Cytotoxicity assay using 
cultured human breast tumor cell lines demonstrated that cancer cells could release 
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incorporated drug from the NPs. These redox-sensitive NPs may be useful as delivery 
platforms for cytotoxic cancer drugs.  
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CHAPTER 3  
REDOX-RESPONSIVE POLYMERIC MICELLES FOR DRUG DELIVERY  
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ABSTRACT 
  
A novel redox-responsive amphiphilic polymer was synthesized with bioreductive 
trimethyl-locked quinone propionic acid for a potential triggered drug delivery 
application. The aim of this study was to synthesize and characterize the redox-
responsive amphiphilic block copolymer micelles containing pendant bioreductive 
quinone propionic acid (QPA) switches. The redox-responsive hydrophobic block 
(polyQPA), synthesized from QPA-serinol and adipoyl chloride, was end-capped with 
methoxy poly(ethylene glycol) of molecular weight 750 (mPEG750) to achieve a redox-
responsive amphiphilic block copolymer, polyQPA-mPEG750. PolyQPA-mPEG750 was 
able to self-assemble as micelles to show a critical micelle concentration (CMC) of 0.039 
% w/v (0.39 mg mL-1, 0.107 mM) determined by a dye solubilization method using 1,6-
diphenyl-1,3,5-hexatriene (DPH) in phosphate buffered saline. The mean diameter of 
polymeric micelles was found to be 27.50 nm (PI = 0.064) by dynamic light scattering. 
Furthermore, redox-triggered destabilization of the polymeric micelles was confirmed by 
1H-NMR spectroscopy and particle size measurements in a simulated redox state. 
PolyQPA-mPEG750 underwent triggered reduction to shed pendant redox-responsive 
QPA groups and its polymeric micelles were swollen to be dissembled in the presence of 
a reducing agent, thereby enabling the release of loaded model drug, paclitaxel. The 
redox-responsive polyQPA-mPEG750 polymer micelles would be useful as a drug 
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delivery system allowing triggered drug release in an altered redox state such as tumor 
microenvironments with an altered redox potential and/or redox enzyme upregulation. 
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3.1. INTRODUCTION 
 Drug delivery system holds great promise as a tool to improve pharmacokinetics 
and therapeutic efficacy of drugs76. In particular, anti-cancer drugs have been an active 
subject of targeted delivery aiming at microenvironment changes occurring at tumor sites 
77. Nanotechnology is emerging as a promising tool for cancer targeted drug delivery 
system because of their favorable distribution at tumor sites based on enhanced 
permeability and retention 78. However, important challenges associated with drug 
delivery systems such as target tissue specificity and drug release rate at systemic sub-
cellular levels to achieve maximum therapeutic efficacy but minimal toxicity often 
remain as obstacles to their successful translation into clinical outcomes. One approach to 
overcome these limitations would be designing multifunctional materials with 
consideration of meaningful pathophysiological changes occurring at a target site. In 
recent years, various drug delivery systems were explored for their properties to release 
encapsulated drug in a triggered manner in response to abnormal tumor 
microenvironments such as acidic pH79, over-expressed enzymes80,  hyperthermia81 and 
altered redox states 82 compared to normal tissues.  
 In cellular systems, redox homeostasis plays pivotal roles in the maintenance of 
cellular functions. Intracellular compartments maintain a certain redox gradient compared 
to the extracellular environment, providing an exciting target for selective intracellular 
chemical release. The redox gradient between intracellular and extracellular 
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compartments in a wounded site is significantly greater than that in healthy tissues, which 
is modulated by intricate networks of redox signaling pathways adapting internal 
environment to the extracellular changes 83. Redox agents expressed during the 
intracellular redox-regulatory processes serve as indicators of the redox status. Redox 
switch materials inspired by these redox agents are appealing tools to be exploited into 
drug delivery systems which enable to release drugs by triggering chemical/physical 
changes upon exposure to an altered reductive environment in cancer 84.  
 Various redox-switches utilized to create multifunctional materials for drug 
delivery applications have frequently been based on diselenide and disulfide bonds.85 
Trimethyl locked quinone propionic acid (QPA) group has also been of interest, as they 
can be reduced to form lactone by intramolecular cyclization of hydroquinone via the two 
electron reduction86. The reduction of the QPA subunits associated with synthetic 
materials has been demonstrated by the adoption of the simulated redox states not only 
with chemical agents such as dithionite and borohydride, but also with reductases such as 
DT-diaphorase (NAD(P)H:quinone oxidoreductase (NQO1), EC 1.6.99.2)87. It is 
interesting to note that DT-diaphorase, a two electron reductase, is highly expressed in 
several cancerous tissues88. Tumors such as non-small cell lung cancer and pancreatic 
cancers have shown to express high levels of DT-diaphorase relative to normal tissue, as 
much as a 20-fold increase28. Hence, QPA-based materials provide a wide range of 
redox-triggered architectures to tune the cleavage of the redox-switch for targeted drug 
delivery to tumors86, 89. Volpato and coworkers prepared an aniline mustard prodrug 
containing QPA group to prove the prodrug activation in vitro selectively by DT-
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diaphorase, comparing to other reductase such as cytochrome p450 reductase86. Their 
study has demonstrated that active aniline mustard could be released from the prodrug via 
DT-diaphorase-mediated bioreduction. Redox-sensitive liposomes comprising a QPA 
head group and dioleoyl phosphatidylethanolamine (DOPE) lipids have also been 
prepared by Ong et al. 34. The researchers have demonstrated that rapid lysis of the 
liposomes resulted in the release of incorporated calcein via liposomal structural 
destabilization upon reduction of QPA head group by dithionite. Recently our group has 
developed redox-responsive polymeric nanoparticles (NPs) with pendant QPA redox 
triggers which aqueous solubility could be reversed upon QPA reduction. These QPA-
based redox–responsive NPs were able to release incorporated paclitaxel under a redox 
state simulated with dithionite. Additionally, in vitro cytotoxicity study has confirmed 
that these NPs could release paclitaxel in the presence of human breast tumor T47D and 
MDA-MD-231 cells. Although these redox-responsive NPs offer advantages as a tumor 
targeted drug delivery system, they were noticeably aggregated in aqueous environment 
because of hydrophobic nature of the polymer82, 90. It has been found that hydrophobic 
polymer nanoparticles have limitations including poor stability in blood during 
circulation and high cytotoxicity for their potential in vivo applications 91. To overcome 
these limitations, we intended to obtain the PEG grafted polymeric drug delivery system 
as the alternative approach mainly because of well-established non-fouling property of 
PEG that prevent the adsorption of plasma protein or the opsonization.92 
In this paper, we describe a novel amphiphilic block copolymer which is designed 
to possess QPA redox switches in the hydrophobic block while hydrophilic PEG block is 
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expected to increase physical stability of resultant NPs. Considering the capability of 
QPA reduction  in the presence of meaningful tumor-associated redox changes, we 
anticipate that polymer micelles consisting of QPA redox switches can be destabilized by 
a solubility reversal occurring in the hydrophobic polymer block of the copolymer due to 
the release of  pendant QPA groups. To our knowledge, this is the first study reporting 
the incorporation of QPA redox switches in the polymeric micellar system for a drug 
delivery application.  
 
 
3.2. EXPERIMENTAL 
3.2.1. Materials 
Methanesulfonic acid, 2,3,5-trimethyl hydroquinone, methyl β,β-
dimethylacrylate, 2-amino-1,3-propanediol, and adipoyl chloride were obtained from 
Alfa Aesar (Ward Hill, MA). Adipoyl chloride was distilled under reduced pressure 
before the reaction. Paclitaxel (PTX) was purchased from LC Laboratories® (Woburn, 
MA). Methoxy poly(ethylene glycol) of molecular weight 750 (mPEG750) from Sigma-
Aldrich (St. Louis, MO) was used after distillation. Acetone-d6 (99.9%, Cambridge 
Isotope Laboratories, Inc., Andover, MA) and deuterium oxide (99.8%, Acros) were used 
for NMR measurements as received. Human DT-diaphorase and reduced dipotassium salt 
β-nicotinamide adenine dinucleotide (β-NADH) were purchased from Sigma-Aldrich (St. 
Louis, MO). All other chemicals purchased from Fisher Scientific (Pittsburg, PA) were 
used as received. 
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Scheme 3.1. Reaction scheme for the synthesis of redox-responsive amphiphilic block 
copolymer, polyQPA-mPEG750, with QPA redox-switches. 
 
3.2.2. Synthesis of amphiphilic redox-sensitive polymer (polyQPA-mPEG750) 
PolyQPA-mPEG750 was synthesized in a two-step reactions shown in Scheme 
3.1.. First, redox-responsive hydrophobic block, polyQPA, was synthesized as reported 
previously82, 90. Briefly, fresh distilled adipoyl chloride diluted in anhydrous THF was 
slowly added into a solution of the monomer, QPA-serinol, at a molar ratio of 1:1 in 
pyridine (10 times molar amount of adipoyl chloride) at room temperature and stirred for 
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30 min. After further polymerization under dry nitrogen at room temperature overnight, 
an additional amount of adipoyl chloride (another 10% of initial molar amount) in THF 
was charged to the reaction mixture and stirred for another six hours. Next, mPEG750 was 
dried by azeotropic distillation using toluene to end-cap polyQPA. Dried mPEG750 in 
THF was added to polyQPA at a molar ratio of 10:1 and the end-capping reaction was 
proceeded for another 16 h. Resultant polyQPA-mPEG750 was precipitated in an excess 
amount of ether and the crude polymer was purified further by rinsing three times with 
methanol to remove unreacted mPEG. The final product polyQPA-mPEG750 was yielded 
as yellow solid (62.1%).  
1H-NMR (CDCl3): δ ppm: 4.37 (14H, s), 4.12 (28H, s), 4.06 (28H, s), 3.64 (90H, s), 3.30 
(6H, s), 2.83 (28H, s), 2.36 (56H, t), 2.12 (42H, s), 1.95 (56H, m), 1.39 (14H, s). 
 
3.2.3. Characterization of polyQPA-mPEG750 
 The chemical structures of the polyQPA-mPEG750 were identified with H1-NMR 
spectrum using a Bruker Avance 400 MHz spectrometer. The NMR spectra were 
measured in CDCl3. The molecular weight and polydispersity index (PDI) of the 
synthesized copolymer were determined with a Waters gel permeation chromatography 
(GPC) system (Waters, Milford, MA). The GPC instrument is equipped with a binary 
pump (Waters 1525), refractive index detector (waters 2414), and a Styragel HR4E 
column (300 × 7.8 mm ID, 5 µm particle size). HPLC grade tetrahydrofuran (THF) was 
run as a mobile phase at a flow rate of 1.0 mL min-1 at 25 °C. Number (Mn) and weight 
average (Mw) molar masses were determined using Breeze software. The molecular 
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weight of the copolymer was calculated using a calibration curve obtained from 
polystyrene standards (Polysciences, Inc., Warrington, PA) of molecular weights ranging 
from 600 to 50,000 g mol-1 in THF.  
 
3.2.4. Preparation of polymeric micelles 
 Drug-free and PTX-loaded polymeric micelles were prepared by a method of a 
solid dispersion technique with a minor modification93. Briefly, PTX (32.2 mg) and 
polyQPA-mPEG750 (150 mg) were completely dissolved in 2 mL of acetonitrile. After 
evaporation of the organic solvent using a rotary evaporator, remaining organic solvent 
was further removed by a vacuum pump overnight to obtain the molecularly dispersed 
PTX in polymer matrix. Three milliliters of phosphate buffered saline (PBS, pH 7.4) 
were added to the mixture to obtain micellar solution by hydration. After being stirred 
overnight in dark at room temperature, the solution was filtered through a 0.2 µm filter to 
remove the unincorporated drug aggregates, followed by lyophilization. The blank 
micelles were prepared by the same procedure without PTX. 
 The loading efficiency of PTX in the micelles was determined by the HPLC 
method previously reported to analyze the amount of PTX in QPA polymer NPs90. The 
drug loading efficiency (%) was calculated according to the following formula.  
PTX loading (%) = (amount of loaded PTX/amount of initially added PTX) × 100 
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3.2.4. CMC measurement 
 The critical micelle concentration (CMC) of the polymer was determined by a dye 
solubilization method using 1,6-diphenyl-1,3,5-hexatriene (DPH)94. Briefly, serially 
diluted polymer solutions in a concentration range of 1.0 × 10-4 to 1.0 wt.% were 
prepared with PBS. Next, 25 µL of 0.4 mM DPH solution in methanol was added into 2.5 
mL of each polymer solution. The mixture was sonicated for 1 min and equilibrated for 
24 h in a dark place. Measurements of UV absorption for each solution were taken on a 
Genesys 6 UV-Visible scanning spectrophotometer (Thermo Scientific, Massachusetts) at 
wavelengths of 377 and 391 nm. The absorbance difference at 377 and 391 nm was 
plotted against polymer concentration. The CMC of polyQPA-mPEG750 was determined 
by reading the polymer concentration at which the extrapolated two lines cross over.  
 
3.2.5. Particle size measurements and redox-responsive polymer degradation 
 The Z-average diameter and polydispersity index (PI) of polyQPA-mPEG750 
micelles were determined by dynamic light scattering using a Zetasizer Nano ZS 
(Malvern Instruments, Worcestershire, UK). A polyQPA-mPEG750 solution at a 
concentration above its CMC was prepared to allow self-assembling into micelles in 
PBS. 
 The effect of QPA reduction on the micellar structure was tested with a chemical 
reducing agent, sodium dithionite (Na2S2O4). QPA lactone release was identified by 1H-
NMR spectrum. A polyQPA-mPEG750 solution at a concentration of 1.5% (w/v) was 
prepared for the NMR measurement using a co-solvent of acetone-d6 and deuterium oxide 
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at a volume ratio of 1:2. The NMR spectrum of release QPA lactone  was measured on 
the NMR spectrophotometer and compared with that of QPA lactone control synthesized 
during polymer synthesis 86. The NMR spectra were periodically taken up to 3 h after the 
addition of sodium dithionite. 
 
3.2.6. Redox-triggered QPA lactone release from polyQPA-mPEG750 micelles 
 QPA lactone release from the micelles was examined by challenging polyQPA-
mPEG750 micelles with two different redox-triggers, sodium dithionite and DT-
diaphorase. A polyQPA-mPEG750 stock solution at a concentration of 10 mg mL-1 (1%) 
in PBS was prepared and diluted to obtain polymer solutions at concentrations of 0.01% 
and 0.5%. Fifteen milligrams of sodium dithionite resulting in a final concentration of 29 
mM was added to 3mL of each polyQPA-mPEG750 solution. In the case of enzymatic 
reduction of QPA, five units of DT-diaphorase and bovine serum albumin (0.007%) were 
added to each PolyQPA-mPEG750 solution. After an addition of an amount of β-NADH 
to achieve a final concentration of 2 mM, 150 µL of the medium was collected and mixed 
into 150 µL of acetonitrile at predetermined time points. All samples were tested in 
triplicate and the study was carried out in a water bath equilibrated at 37 °C. Amounts of 
QPA lactone released upon reduction were analyzed using the HPLC method previously 
reported. A HPLC system equipped with a Luna C18(2) HPLC column (Phenomenex, 
150 x 4.6 mm, 5 µm), a binary pump (Waters 1525), and an auto-sampler (Water 717) 
was used to run a mixture of acetonitrile and water at 55/45% v/v  as a mobile phase at a 
flow rate of 1 mL min-1 after injecting a 20 µL sample 95. Released QPA lactone was 
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detected at a wavelength of 227 nm on a UV detector (Water 2487). The amount of 
released lactone was calculated using a calibration curve obtained from known 
concentrations of QPA lactone solutions in acetonitrile. 
 
3.2.7. In vitro drug release study 
 In vitro drug release from polyQPA-mPEG750 micelles was examined by 
challenging the micellar solution with sodium dithionite to reduce QPA groups after 
loading PTX in micelles as a model drug. Based on a HPLC measurement performed 
prior to drug release study, it was shown that one milligram of polyQPA-mPEG750 
micelle contained 177.4 µg of PTX. One hundred microliter of 0.5% of PTX loaded 
polymer micelles containing 88.7 µg of PTX was used for the study.  Forty milliliters of 
PBS including sodium salicylate at a concentration of 0.8 M were used for redox-
triggered drug release. After placing polyQPA-mPEG750 micelle in a dialysis membrane 
of MWCO 1,000 Da (Spectrum Laboratories), the dialysis membrane was immersed in 
drug release media equilibrated at 37 °C and the release media were continuously 
agitated by magnetic stirring. For redox-triggered PTX release from polyQPA-mPEG750 
micelles, an amount of sodium dithionite to achieve a final concentration of 29 mM was 
added in the medium. In addition, the solution consisting of PTX (88.7 µg) was utilized 
as a control. Samples were withdrawn from the release medium at predetermined time 
points and were analyzed by HPLC. 
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3.2.8. Cell culture 
 Human breast tumor T47D and MDA-MB-231 cells lines were purchased from 
ATCC, Manassas, VA and used in this work. These cell lines were cultured in 
DMEM/F12 medium containing 2.5 mM L-glutamine (Mediatech), supplemented with 
fetal bovine serum (FBS, 10% v/v final concentration, Hyclone), penicillin G (sodium 
salt, 50 units mL-1) and streptomycin sulfate (50 µg mL-1) (BioWhittaker). Exponentially 
grown cells were plated at the density of 30,000 cells per well into 96-well plates in a 
volume of 100 µL culture media and incubated at 37 °C in a humidified environment 
(95% air, 5% CO2) as previously reported 61. 
3.2.9. In vitro antitumor activity of polyQPA-mPEG750 micelles 
 The cytotoxicity of PTX formulated in polyQPA-mPEG750 was evaluated in 
human breast tumor T47D and MDA-MB-231 cells lines, in comparison to free PTX. 
Briefly, after seeing in 96-well plates followed by overnight attachment, the cells were 
treated by PTX-loaded micelles with varied concentrations. Free PTX, at concentrations 
equivalent to the PTX incorporated in micelles, was also added into cells. After treatment 
for 24 h, the cells were further incubated and cell viability was determined by a 
sulforhodamine B (SRB) method 62. Optical density (OD) was measured at 490 nm with 
background absorption at 630 nm. Data were normalized to the untreated control and 
presented as ‘% of control,’ using the formula. 
   Cell viability (% of Control) = (ODtreated/ODcontrol) × 100                         
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3.2.10. Statistical analysis 
 Experimental measurements were triplicated for each sample. The results are 
presented as mean ± standard deviation. The statistical analysis of experimental data 
utilized the student’s t-test and statistical significance was considered for P-values < 0.05. 
 
 
3.3. RESULTS 
3.3.1. Synthesis and Characterization of polyQPA-mPEG750 
 PolyQPA-mPEG750, designed for redox-responsive polymer micelles, were 
synthesized as illustrated. After synthesis of hydrophobic block, polyQPA, as presented 
in Scheme 3.1, the following reaction with an additional amount of adipoyl chloride 
provided reactive end groups in polyQPA. The reactive polyQPA underwent end-capping 
with mPEG of molecular weights 750 to achieve redox-sensitive block copolymers. The 
1H-NMR spectrum of polyQPA-mPEG750 in Figure 3.1. showed the peaks of mPEG at δ 
= 3.64 ppm (-CH2CH2O-) and 3.37 ppm (CH3O-) in CDCl3. Moreover, three methyl 
(CH3-) protons of quinone was presented at 1.95-1.96 and 2.12 ppm. Resultant polyQPA-
mPEG750 was obtained as a yellow solid exhibited good water solubility.  
 Number average molecular weight (Mn) and polydispersity (PDI) of the redox-
sensitive block copolymer were determined to be 3640 and 1.65, respectively, by GPC.  
Clear shift in the molar mass distribution to shorter retention times was observed. Before 
the end-capping of the PEG at the end of the hydrophobic group, the molecular weight of 
hydrophobic polymer was calculated as 2482 with PDI of 1.37 by GPC measurements.  
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Figure 3.1. 1H-NMR spectrum of polyQPA-mPEG750 in CDCl3. The letters denote peak 
assignments in 1H-NMR spectra. 
 
3.3.2. Micelle formulation  
 The ability of polyQPA-mPEG750 to self-assemble into micelles was examined by 
a CMC measurement. The CMC of polyQPA-mPEG750 was determined by a method 
based on hydrophobic dye solubilization as shown in Figure 3.2.. At a concentration 
below CMC, amphiphilic polyQPA-mPEG750 was not able to increase DPH solubility, 
resulting in inadequate UV absorbance. A dramatic increase in UV absorbance was 
observed at a polymer concentration greater than CMC. The CMC was determined by a 
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graphical extrapolation of two phases of UV absorbance changes and reading out the 
polymer concentration at which they crossed over. The CMC of polyQPA-mPEG750 in 
PBS was found to be 0.039% w/v (0.39 mg mL-1, 0.107 mM) at 25 °C. 
 
Figure 3.2. (A) Determination of the critical micelle concentration of polyQPA-mPEG750 
using DPH. The difference in the absorbance intensities of DPH at wavelengths of 377 
and 391 nm was plotted as a function of polyQPA-mPEG750 concentration. CMC was 
determined by reading out the point, A, at which two extrapolated lines were crossed. (B) 
A representative particle size distribution of drug-free micelles was obtained by DLS 
measurement at 25 ± 1 °C. Determined average particles size was 27.50 nm with a PI of 
0.064.  
 Both PTX-free and PTX-loaded polymeric micelles were prepared by a solid 
dispersion technique which was also applied to prepare for PTX-loaded polymer micelles 
from monomethoxy poly(ethylene glycol)-block-poly(D,L-lactide) (mPEG-PDLLA)93. 
During the process of micelle preparation, the amount of residual acetonitrile, the solvent 
to dissolve polyQPA-mPEG750 and PTX, was under the detection limit by 1H NMR 
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spectroscopy measurements after vacuum drying. A simple hydration of the mixture of 
polyQPA-mPEG750 and PTX with PBS enabled to produce micelle formulations. 
The mean diameter of resultant PTX-free micelles was determined to be 27.50 nm 
with a PI of 0.064 at 25 ± 1 °C by DLS as presented in Figure 3.2. However, the average 
size of PTX-loaded micelles was 79.92 nm, which was noticeably larger than that of 
PTX-free micelles. The amount of PTX loaded in 1 mg of polyQPA-mPEG750 micelles 
was found to be 177.4 µg indicating a loading content of 17.74% while drug loading 
efficiency was found to be 82.5%.  
 
3.3.3. Redox-responsive polymer degradation 
PolyQPA-mPEG750 was examined for its reduction in the presence of a redox chemical. 
Since we are interested in redox-triggered drug release from polyQPA-mPEG750 micelles, 
we primarily focused on the characterization of dimensional changes occurring to the 
micelles in the presence of a redox chemical. This would be eventually translated into 
drug release. As shown in Figure 3.3., the micellar size based on averaged volume has 
significantly changed upon the addition of a redox chemical, sodium dithionite. The size 
of polyQPA-mPEG750 micelles rapidly increased from 28 nm to 64 nm within 5 min after 
the addition of sodium dithionite while no noticeable change in micellar size was 
observed from the control without sodium dithionite. The average size of micelles further 
increased to reach 3338 nm at a time point of 30 min. The increase in polyQPA-mPEG750 
micelle size in the presence of sodium dithionite is attributed to the solubility reversal 
occurred to the hydrophobic polyQPA core which would become hydrophilic after the 
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removal of hydrophobic pendant QPA groups via intramolecular cyclization. In addition, 
PI of the NPs increased over three hours indicating more heterogeneous particle 
population. 
  
Figure 3.3. Redox-triggered particle size change in polyQPA-mPEG750 micelles was 
monitored by dynamic light scattering measurements in the presence or absence of 
sodium dithionite. 
 
 The effect of sodium dithionite on polyQPA-mPEG750 was directly examined by 
NMR measurement. Figure 3.4.(A) has shown reduction mechanism of QPA switches in 
polyQPA-mPEG750 copolymer with sodium dithionite and the letters in Figure 3.4.(A) 
indicate peak assignments in 1H-NMR spectra. After dissolving polyQPA-mPEG750 in a 
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co-solvent of acetone-d6 : D2O (2:1, v/v) to warrant the solubility of both lactone and 
copolymer, NMR spectra were periodically recorded with or without sodium dithionite 
shown in Figure 3.4 (B 1-3).    
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Figure 3.4. (A) Reduction mechanism of redox-switches in polyQPA-mPEG750 
copolymer using sodium dithionite and release of QPA lactone. The letters denote peak 
assignments in 1H-NMR spectra. (B) 1H-NMR spectra (400 MHz) of polyQPA-mPEG750 
were recorded in acetone-d6 and deuterium oxide (1.5%, 1:2, w/v) before (B-1) and after 
(B-2, 30 min, and B-3, 3 h) an addition of sodium dithionite at a concentration of 29 mM. 
The NMR spectrum of lactone (B-4) is also measured for comparison. 
 
Figure 3.4. (B) also includes the NMR spectrum of QPA lactone as control to compare 
with (Figure 3.4. (B-4)). When sodium dithionite was added into micelle solution, all 
proton peaks in NMR spectra (Figure 3.4. (B)) were slightly shifted (< 0.25 ppm) 
compared to the one recorded before adding sodium dithionite. This result is because of 
ionic strength changes in the NMR sample solution and the similar result were presented 
in the reported publication 96. The addition of sodium dithionite also resulted in the 
appearance of proton peaks attributed to six protons of methyl groups in QPA lactone at δ 
= 1.33 ppm. In addition, 30 min after the initiation of reduction, the proton peak from 
QPA pendant groups in polyQPA-mPEG750 (-COCH2C-) has shifted from δ = 2.75 to 
2.51 ppm, indicating the QPA lactone formation by intramolecular cyclization. 
  
3.3.4. Redox-triggered QPA lactone release from polyQPA-mPEG750 micelles 
 In order to quantitatively analyze QPA reduction in polyQPA-mPEG750 micelles, 
the amount of QPA lactone released from polyQPA-mPEG750 was measured as a function 
of time in the presence and absence of the redox agent. As shown in Figure 3.5, there was 
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no noticeable QPA lactone release from the control which did not contain the redox 
agent. QPA reduction in polyQPA-mPEG750 micelles was rapid enough to release 
60.04% and 67.04% of QPA groups at polymer concentrations of 0.01 and 0.50%, 
respectively in 30 min after the initiation of the reduction. Cumulative QPA lactone 
release reached to 85.30% and 72.62% within 24 hours at polymer concentrations of 
0.01% and 0.50%, respectively. At 48 hours after the addition of sodium dithionite, QPA 
lactone generated from 0.01% of polyQPA-mPEG was 88.09% which reveals no 
statistically significant differences (two-tailed t-test, p > 0.05) even after 48 hours of 
incubation. 
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Figure 3.5. Redox-triggered QPA lactone release from polyQPA-mPEG750 solution in 
PBS buffer (pH 7.4) at 37 °C. Cumulative QPA lactone release from polyQPA-mPEG750 
at concentrations of 0.50% (A) and 0.01% (B) was plotted as a function of time after an 
addition of each reducing agent, sodium dithionite (●) or DT-diaphorae/β-NADH (∆). 
The control (×) was copolymers without those reducing agents.   
 
 In addition, polyQPA-mPEG750 micelles were also able to release QPA lactone 
via redox enzyme-mediated bioreduction. Indeed, DT-diaphorase could trigger QPA 
reduction to result in spontaneous QPA lactone release from hydrophobic cores of 
polyQPA-mPEG750 micelles. DT-diaphorase-mediated QPA reduction, however, was 
dependent on polymer concentration. Cumulative amounts of QPA lactone released by 5 
units of DT-diaphorase in the presence of 2 mM of a cofactor β-NADH at 37 °C reached 
to 61.84% and 20.87% at polymer concentrations of 0.01% (Figure 3.5. (B)), a 
concentration below CMC, and 0.50% (Figure 3.5. (A)), a concentration above CMC, 
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respectively. This result indicated that the supramolecular structure of polyQPA-mPEG750 
assembly could  affect the efficiency of DT-diaphorase-mediated QPA reduction.  
 
3.3.5. In vitro PTX release from polyQPA-mPEG750 micelles 
 In vitro PTX release from polyQPA-mPEG750 micelles, examined by a dialysis 
method in the presence of sodium dithionite, demonstrated that QPA reduction in 
polyQPA-mPEG750 micelles could trigger the release of incorporated PTX. As seen in 
Figure 3.6, polyQPA-mPEG750 micelles have released only 17.08% of loaded PTX over a 
period of 36 h in the absence of sodium dithionite. An addition of the redox agent into the 
polyQPA-mPEG750 micellar solution has dramatically increased the release of PTX 
resulting in a significant increase in cumulative release of PTX from 18.20% to 52.53% 
between time points 3 h and 12 h, respectively (p < 0.05). The cumulative PTX release 
has further increased to 65.73% at 36 h after triggering QPA reduction. Triggered PTX 
release from polyQPA-mPEG750 micelles was comparable to the PTX release profile 
from pure PTX solution. 
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Figure 3.6. Redox-triggered PTX release from polyQPA-mPEG750 micelles in the 
presence (■) and absence (○) of sodium dithionite (29 mM) at 37 °C. An addition of PTX 
solution with sodium dithionite was used as the control to compare with (×). 
 
3.3.6. In vitro antitumor activity of polyQPA-mPEG750 micelles 
 Concentration-dependent cell cytotoxicity studies were performed to determine 
the effects of PTX-loaded polyQPA-mPEG micelles on the proliferation/viability of 
human breast tumor cells. As shown in Figure 3.7. (A), at a drug dose of 0.1 µM, cell 
viabilities of 20% and 24% were observed for MDA-MB-231 cell line following 24 h of 
incubation with free PTX and PTX-loaded micelles, respectively. The cell experiment for 
T47D cell line in Figure 3.7. (B) also showed similar cell viability, in which 22% and 
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26% of cell viability were observed for plain drug, PTX loaded micelles, respectively.  
The IC50 (i.e., inhibitory concentration to produce 50% cell death) of PTX-loaded 
micelles, were 217.6 µM and 277.0 µM for MDA-MB-231 and T47D cell lines, 
respectively, while those of free PTX were 323.3 µM and 296.1 µM.  
 
 
Figure 3.7. Effects of paclitaxel loaded micelles on human breast tumor cell 
proliferation/viability determined by SRB method: (A) MDA-MB-231 cells (B) T47D 
cells. Exponentially grown T47D and MDA-MB-231 cells were exposed to the different 
concentration of PTX-loaded micelles (•) and PTX (×) for 24 h under normoxic condition 
(95% air : 5% CO2). Data shown are average standard deviation (n=3). 
 
3.4. DISCUSSION 
 We have previously reported QPA-based redox-responsive polymeric NPs 
enabling drug release under a simulated redox state. In this study, we developed a redox-
responsive amphiphilic block copolymer containing QPA triggers, polyQPA-mPEG750, 
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which is able to self-assemble into micelles, load a hydrophobic drug, and release the 
drug in response to a redox change. Redox-responsive copolymers were synthesized in a 
two-step reaction. In the first step in Scheme 3.1, hydrophobic polyQPA block was 
synthesized by esterification between QPA-serinol and adipoyl chloride as previously 
reported.82,90 The esterification was occurred by the reaction between two hydroxyls in 
QPA-serinol and reactive two acyl chloride groups in adipoyl chloride. For the following 
end-capping of polyQPA with mPEG, both terminal functional groups needed to be 
identically reactive towards the hydroxyl group of mPEG. Since terminal functional 
groups of polyQPA could be either hydroxyl or acyl chloride, an additional amount of 
adipoyl chloride was added to secure reactive acyl chloride groups at both ends. The 
activated polyQPA was reacted with dried mPEG750 to obtain redox-sensitive amphiphilic 
polyQPA-mPEG. Based on molecular weight analysis, molecular weights of polyQPA-
mPEG750 and polyQPA, 3640 and 2482 respectively, may indicate that polyQPA-
mPEG750 possesses mixture of tri-block copolymer and diblock copolymer with 
consideration of mPEG molecular weight 750.  
 Self-assembling of polyQPA-mPEG750 into micelles was supported by 
demonstration of CMC. The CMC of polyQPA-mPEG750 was 0.039% w/v, which is 
lower than commercially available amphiphilic tri-block copolymers, poly(ethylene 
glycol)-poly(propylene glycol)-poly(ethylene glycol) (Pluronic®). CMCs of Pluronic® 
polymers range from 0.6% to 4% 97. Partiucularly, Pluronic® L64 (MW of 3400 and a 
PEG content of 40%), which has molecular characteristics similar to polyQPA-mPEG750 
(MW of 3600 and a PEG content of 41%), has a CMC of 4% w/v. It is well established 
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that self-assembling of amphiphilic block copolymers into micelles is primarily 
dependent on the nature and length of hydrophobic block.97-98  The determined CMC of 
polyQPA-mPEG750 lower than that of Pluronic® L64 may indicate that polyQPA is more 
hydrophobic than poly(propylene glycol).  
 Particle size of polyQPA-mPEG750 measured by dynamic light scattering has 
shown that micellar sizes of drug-free and drug-loaded micelles were in a range between 
20 nm and 100 nm. It should also be noted that the size of PTX-free polyQPA-mPEG750 
micelles was smaller than that of drug-loaded micelles. It has been reported that loading a 
hydrophobic drug in the core of polymer micelle often expands micelles and increases 
micelle size.99 PolyQPA-mPEG750 micelles, both drug-free and drug-loaded, were smaller 
than other nanocarriers with QPA redox switches such as liposome 34 and nanoparticles 90 
of which particles sizes were ~100 nm and 249.8 nm, respectively. It has been suggested 
that drug carriers within a size range between 10 nm and 200 nm would avoid 
reticuloendothelial system (RES)-mediated particle clearance, which would be beneficial 
for a prolonged systemic circulation.100 Considering particle size and protective PEG 
brushes on surface, polyQPA-mPEG750 micelles would be useful for drug delivery 
applications. 
 Generally, hydrophobic drug loading into micellar structures is affected by 
molecular interactions between a drug and hydrophobic micelle core and steric factors 
101. In this study paclitaxel was utilized as a model hydrophobic drug to assess the 
application of prepared micelles to drug delivery. Our previous publication reported that 
the Flory-Huggins interaction parameter (χ) between polyQPA and PTX was estimated to 
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be 0.031 by solubility parameters calculated from the Molecular Dynamic simulations, 
suggesting a good miscibility 90. Indeed, a relatively high PTX loading efficiency of 
82.5% as well as a drug loading content of 18% was achieved with polyQPA-mPEG750 
micelles. Such favorable drug loading might cause more than two-fold increase in micelle 
size from 27.50 nm to 79.92 nm, which is comparable to other biodegradable polymer 
micelles incorporated with hydrophobic drugs 100. 
 
Scheme 3.2. Schematic illustration of drug release from redox-responsive polyQPA-
mPEG750 micelles upon redox-triggered QPA reduction. 
 
 For a successful application of polyQPA-mPEG750 micelles as a drug delivery 
system, redox-triggered dissembling of the micelles and subsequent drug release are very 
important. Therefore, polyQPA-mPEG750 micelles were tested for their redox-triggered 
dimensional changes and drug release. As illustrated in Scheme 3.2, drug-incorporated 
micelles are stable in the absence of sodium dithionite. However, in the presence of 
sodium dithionite these micelles are expected to expand upon initiation of QPA reduction 
in the hydrophobic core thereby releasing the entrapped drug. It has been previously 
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reported that hydrophobic polyQPA undergoes a solubility reversal by exposing free 
amine groups after QPA lactone release via spontaneous intra molecular cyclization in 
the presence of the redox trigger 82, 90. With protonation of exposed free amine groups in 
pH 7.4, the size of polymeric micelles should increase by swelling due to the repulsive 
ionic interactions introduced after the removal of QPA lactone. As expected, polyQPA-
mPEG750 micelles started to rapidly swell to reach 3338 nm (PI~1.0) within 30 min after 
the initiation of QPA reduction, indicating that micelle cores were swollen because of 
polymer hydration induced by the solubility reversal occurred in the polyQPA block. 
Swollen micelles with loosely interwoven polymer chains in the core would be able to 
facilitate the release of incorporated PTX. This unique property of redox-triggered 
dimensional changes in polyQPA-mPEG750 micelles may be useful for targeted drug 
delivery to the tissues with altered redox state such as tumors. 
 Redox-triggered structural change in polyQPA-mPEG750 was also examined by 
NMR measurements to mechanistically correlate the effect of the redox trigger on the 
molecular property changes in the polymer which could be related to drug release. 
Yellow polyQPA-mPEG750 solution became colorless implying that QPA groups were 
reduced to hydroquinone. The NMR spectrum recorded at 30 min after the addition of 
sodium dithionite showed characteristic proton peaks of QPA lactone, reduced polyQPA-
mPEG750 backbone and partially reduced quinone (Figure 3.4.(B-2)). In particular, the 
characteristic QPA lactone peaks (Figure 3.4. (B-3)) recorded in 3 h appeared after 
polymer reduction match with the peaks in the NMR spectrum measured with QPA 
lactone control (Figure 3.4. (B-4)), which indicates successful QPA group reduction. 
88 
 
Combining the experimental results of redox-triggered dimensional changes in micelles 
and structural changes in polyQPA-mPEG750, the redox-responsive polyQPA-mPEG750 
micelles could be swollen by redox-triggered QPA lactone release within 30 min as 
presented in Scheme 3.2.. 
 Quantitative analysis of lactone was assessed to get further informative insight 
into the underlying physical and chemical reduction processes of redox-responsive 
micelles, which can be eventually translated into drug release. The QPA lactone release 
profile in Figure 3.5. has clearly demonstrated that most QPA in the core of polyQPA-
mPEG750 micelles was as a lactone form in the presence of sodium dithionite regardless 
of polymer concentration. This result is consistent with QPA reduction on polyQPA-
mPEG750 characterized by NMR measurements (Figure 3.4). It also worth mentioning 
that PEG block attachment did not affect QPA lactone release from polyQPA. QPA 
lactone release from polyQPA-mPEG750 micelles was similar to that from polyQPA NPs. 
82, 90 Considering the degradation of polyQPA-mPEG750 backbone chain, a change of its 
hydrophobicity due to carboxylic acid ends liberated by cleavage of their ester bonds will 
facilitate the reduction of QPA group which leads to an immediate QPA lactone release 
(Figure 3.5.). As shown in Figure 3.5., enzymatic reduction of polyQPA-mPEG750 was 
noticeably different from that with sodium dithionite. A redox enzyme often upregulated 
in tumors, DT-diaphorase, could release QPA lactone from polyQPA-mPEG750. 
However, the enzymatic QPA reduction on polyQPA-mPEG750 was clearly affected by 
polymer concentration, indicating that a steric factor is involved in DT-diaphorase-
mediated QPA reduction from polyQPA-mPEG750 as seen in Figure 3.5. DT-diaphorase 
89 
 
was able to reduce QPA on polyQPA-mPEG750 when the polymer concentration, 0.01%, 
was below CMC, 0.039% w/v. When polymer concentration, 0.5%, increased to above 
CMC, however, DT-diaphorase was not effective in reducing QPA groups. This result 
indicates that the enzyme had a limited access to QPA groups on polyQPA-mPEG750 
when the polymer assembled into micelles. The QPA groups in the hydrophobic block 
would be hidden inside the micelle core and also masked by the PEG layer on micelle 
surface. This explanation may be valid based on the reported work with N-(2-
hydroxypropyl)methacrylamide micelles containing hydrophobic oligopeptide side 
chains. Ulbrich et al. demonstrated that the penetration of enzyme into micelle core was 
impeded by structural hindrance, thereby preventing the effective enzyme binding to 
substrate 102. However, hydrophilic PEG blocks might contribute to increasing water 
solubility of polyQPA and facilitating the binding between DT-diaphorase and QPA 
groups on polyQPA-mPEG750 under a polymer concentration below CMC since most 
polymer molecules exist as a unimer instead of being associated. The collective results 
also indicated the process of QPA lactonization plays an important role during the 
destabilization process of micelle, thereby enabling the release of loaded drug.  
 In vitro PTX release kinetics, indeed, was well correlated with QPA reduction and 
QPA lactone release previously discussed. PTX release from polyQPA-mPEG750 micelles 
in the presence of sodium dithionite was significantly (p < 0.01) greater than drug release 
in the absence of the redox chemical (Figure 3.6.). PTX release from the micelles was 
even very similar to that from the control, PTX solution itself (two-tailed t-test, p > 0.2) 
assuring that most of incorporated drug was released from the polyQPA-mPEG750 
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micelles over a period of experiment time in the presence of the redox chemical. Overall 
a cumulative PTX release of greater than 80% was comparable to that reported from our 
previous work with polyQPA NPs 90. Based on the results presented in Figures 3.5. and 
3.6., PTX-loaded redox-responsive polyQPA-mPEG750 micelles were stable in aqueous 
environments and able to release the incorporated PTX by redox-triggered QPA 
reduction which disrupted micelle structure.   
 The antitumor activity of polyQPA-mPEG750 micelles was studied in human 
breast tumor T47D and MDA-MB-231 cells to determine cancer cell mediated drug 
release. Free PTX was used as positive controls for the study. As shown in Figure 3.7, a 
concentration-dependent cell-killing effect was shown for PTX-loaded micelles. These 
PTX-loaded micelles inhibited cell proliferation and viability to the comparable extent as 
that observed in the presence of PTX. This result may indicate an increased cellular 
uptake of PTX-loaded polyQPA-mPEG micelles owing to hydrophilic PEG chain on the 
surface and release all incorporated PTX from micelles to limit tumor cell growth. 
Indeed, the similar result was presented in the reported publication.103 When doxorubicin 
was delivered by poly(DL-lactic-co-glycolic acid)-mPEG2000 micelles exhibited greater 
uptake by HepG2 cells, compared to free drug because there is no specific affinity 
between the outer PEG chains of micelles and negatively charged plasma membrane of 
the cells.103 It seemed that the PEG-grafted redox-responsive polymeric micelle would 
resist opsonization and phagocytic clearance and enable to release the loaded drug to 
limit tumor cell growth. The antitumor activity of these polyQPA-mPEG750 micelles may 
be boostered by decorating the hydroxyl end of redox-responsive micelle, polyQPA-
91 
 
mPEG750, with a targeting ligand such as antibody fragment and folic acid which improve 
its specificity for drug delivery through active pathway.104 These polyQPA-mPEG750 
micelles have integrated features including relatively high drug loading, micellar 
stability, redox-triggered dimensional change, and redox-mediated drug release, which 
collectively provide a useful delivery platform for cytotoxic cancer drugs. 
 
 
3.5. CONCLUSIONS 
 A novel redox-responsive amphiphilic polymer comprising QPA redox switches 
and hydrophilic mPEG, polyQPA-mPEG750, was successfully synthesized and 
characterized. Coupling of mPEG to hydrophobic polyQPA provided polyQPA-mPEG750 
with improvement of water-solubility as well as self-assembling capability into micelles. 
Furthermore, incorporation of QPA redox switches into amphiphilic polymer led to 
unique micelles which enable to rapidly undergo dimensional changes upon QPA 
reduction and thus release incorporated drug in a redox-triggered manner. PTX-loaded 
polyQPA-mPEG750 micelles, indeed, has demonstrated a redox-responsive drug release. 
Redox-responsive polyQPA-mPEG750 micelles may be useful as a drug delivery system 
targeting tumor microenvironments which frequently show altered redox state and/or 
redox enzyme upregulation. 
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CHAPTER 4 
NITROREDUCTASE-TRIGGERED ACTIVATION OF A NOVEL CAGED 
FLUORESCENT PROBE OBTAINED FROM METHYLENE BLUE   
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ABSTRACT 
 
 A novel NIR fluorescent probe, p-nitrobenzyl 3,7-bis(dimethylamino)-10H-
phenothiazine-10-carboxylate was developed from methylene blue for the selective 
imaging and therapy. Conjugating methylene blue with a p-nitrobenzyl moiety redox 
switch enables it to quench electron transfer within the molecules, thereby leading to 
improvements in achievable target-to-background auto-fluorescence ratio. Moreover the 
redox trigger caged probe is readily activated by nitroreductase-catalyzed 1,6-
elimination, resulting in the release of active methylene blue fluorophore. This 
fluorescent probe exhibits neither significant NIR fluorescence intensity nor absorbance 
between 500 nm to 800 nm. However, it was activated to release the strong fluorescence 
(λmax = 680 nm) with the excitation at 580 nm upon nitroreductase-mediated two-electron 
reduction of the redox switch. In addition, the fluorescence emission was induced by 
incubation with live Escherichia coli bacteria. It was demonstrated that the NIR 
fluorescent probe generated singlet oxygen after nitroreductase mediated reduction with a 
laser irradiation at a wavelength of 634 nm. The redox trigger caged NIR fluorescent 
probe would be a suitable imaging sensor to detect bacteria expressing NTR. In addition, 
p-NBMB also possesses potential as an MB prodrug which can be applied for the 
treatment of various diseases.  
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4.1. INTRODUCTION 
 Nitroreductase (NTR), a flavin mononucleotide (FMN) cofactor dependent 
protein expressed in Escherichia coli (E. coli), catalyzes reduction of a nitro group to 
hydroxylamine, which is subsequently converted to an amine in the presence of 
nicotinamide adenine dinucleotide phosphate (NAD(P)H) as a cofactor.105 The large 
electronic change resulting from conversion of the electron-withdrawing nitro group to 
the electron-donating hydroxylamino group provides a selective ‘switch’ mechanism for 
the activation of an inert compound which leads to the subsequent release of the active 
agent. Based on this switch mechanism, various prodrug or activatable imaging probes 
have been designed with nitro groups as substrates to be triggered upon reduction by 
NTR.106 The dicoumarin carbonate-based latent fluorophore was devised for the 
application in imaging to improve selectivity for NTR and aqueous solubility.106b 
Furthermore, NTR was employed in development of gene-directed enzyme prodrug 
cancer therapies (GDEPT), antibody-directed enzyme prodrug therapy (ADEPT) and 
drug screening as exemplified with 2,4-dinitrobenzamide (CB1954).107 The basis of 
CB1954 activation has been fully elucidated and the molecule has  advanced into clinical 
trials.35  
 Despite the previous extensive investigation about the use of nitrobenzyl redox 
switches for NTR activatable materials, these switches have not been applied for the 
development of bifunctional compounds, which can serve as a tool for selective imaging 
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and therapy.2-4 To design NTR activatable agents with combined imaging and therapeutic 
function, the selection of an appropriate reporter is of great importance. Among various 
reporters, fluorophores with emission in the far red and near-infrared (NIR), in the range 
of 600-1000 nm, are widely utilized in relevant research settings to overcome the 
limitation of poor tissue penetration owing to the interference from background auto-
fluorescence from biomolecules.8-9 In addition, NIR fluorophores offer several additional 
advantages over conventional imaging agents including high resolution, sensitivity and 
non-invasiveness.108 In particular, methylene blue (MB) has been recognized as a 
sensible starting point for the development of a better NIR fluorophore given MB’s 
strong absorption of broadband red light (550-700 nm, maximum at 664 nm), a 
wavelength at which absorption and autofluorescence are minimal.109  Moreover, MB has 
been applied for clinical therapeutic purposes including treating methemoglobinemia, 
Barrett’s esophagus, and cervical cancer.110 Nitroreductase (NTR), a flavin 
mononucleotide (FMN) cofactor dependent protein expressed in Escherichia coli (E. 
coli), catalyzes reduction of a nitro group to hydroxylamine, which is subsequently 
converted to an amine in the presence of nicotinamide adenine dinucleotide phosphate 
(NAD(P)H) as a cofactor.105 The large electronic change resulting from conversion of the 
electron-withdrawing nitro group to the electron-donating hydroxylamino group provides 
a selective ‘switch’ mechanism for the activation of an inert compound which leads to the 
subsequent release of the active agent. Based on this switch mechanism, various prodrug 
or activatable imaging probes have been designed with nitro groups as substrates to be 
triggered upon reduction by NTR.106 The dicoumarin carbonate-based latent fluorophore 
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was devised for the application in imaging to improve selectivity for NTR and aqueous 
solubility.106b Furthermore, NTR was employed in development of gene-directed enzyme 
prodrug cancer therapies (GDEPT), antibody-directed enzyme prodrug therapy (ADEPT) 
and drug screening as exemplified with 2,4-dinitrobenzamide (CB1954).107 The basis of 
CB1954 activation has been fully elucidated and the molecule has  advanced into clinical 
trials.35  
 Despite the previous extensive investigation about the use of nitrobenzyl redox 
switches for NTR activatable materials, these switches have not been applied for the 
development of bifunctional compounds, which can serve as a tool for selective imaging 
and therapy.2-4 To design NTR activatable agents with combined imaging and therapeutic 
function, the selection of an appropriate reporter is of great importance. Among various 
reporters, fluorophores with emission in the far red and near-infrared (NIR), in the range 
of 600-1000 nm, are widely utilized in relevant research settings to overcome the 
limitation of poor tissue penetration owing to the interference from background auto-
fluorescence from biomolecules.8-9 In addition, NIR fluorophores offer several additional 
advantages over conventional imaging agents including high resolution, sensitivity and 
non-invasiveness.108 In particular, methylene blue (MB) has been recognized as a 
sensible starting point for the development of a better NIR fluorophore given MB’s 
strong absorption of broadband red light (550-700 nm, maximum at 664 nm), a 
wavelength at which absorption and autofluorescence are minimal.109  Moreover, MB has 
been applied for clinical therapeutic purposes including treating methemoglobinemia, 
Barrett’s esophagus, and cervical cancer.110 MB is also known to be photodynamically 
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active so that it can inactivate viruses, destroy bacteria, and inhibit cancer cell growth.109b, 
111 Given its advantageous properties, MB may be an ideal compound to use in design of 
an NTR-switchable probe with both imaging and therapeutic capability. In this study, we 
describe a novel NIR fluorescent probe, p-nitrobenzyl 3,7-bis(dimethylamino)-10H-
phenothiazine-10-carboxylate (p-NBMB) which can be triggered by NTR. To obtain a 
MB-based latent fluorescent probe, which is activatable, a p-nitrobenzyl moiety as an 
NTR switch was conjugated to cage MB at the nitrogen of the phenothiazine ring through 
a carbamate bond, thereby quenching electron transfer within the molecule (Scheme 
4.1.). This ultimately leads to improvements in achievable target-to-background auto-
fluorescence ratios. In the presence of NTR, the resultant caged fluorescent probe is 
 
Scheme 4.1. Mechanism of switching on the fluorescence probe, p-NBMB, upon 
reduction of a p-nitrobenzyl moiety after nitroreductase-mediated activation. 
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intended to be turned back on undergoing reduction of the aryl nitro group. Subsequently, 
the benzyl moiety will be removed by a rapid 1,6-elimination (Scheme 4.1.). We 
primarily assessed the feasibility of whether a novel p-NBMB can be developed into an 
NTR selective activatable agent. Additionally, a potential therapeutic application of the 
compound in photodynamic therapy was also addressed. 
 
4.2. EXPERIMENTAL 
4.2.1. Materials 
 4-Nitrobenzyl chloroformate, nitroreductase from Escherichia coli (E. coli), 
human DT-diaphorase, β-nicotinamide adenine dinucleotide, reduced dipotassium salt 
hydrate (NAD(P)H), and p-nitrosodimethylaniline were purchased from Sigma-Aldrich 
(Saint Louis, MO). Certified grade methylene blue (MB) was obtained from Acros 
Organics (Pittsburgh, PA). All other chemicals were purchased from Fisher Scientific 
(Pittsburgh, PA) and used as received.  
 
4.2.2. Synthesis of p-nitrobenzyl 3,7-bis(dimethylamino)-10H-phenothiazine-10-
carboxylate (p-NBMB)  
  Methylene blue (MB, 373.9 mg, 1 mmol) was dissolved in 10 mL of deionized 
water.  Toluene (40 mL), sodium bicarbonate (292.4 mg, 3.48 mmol) and sodium 
dithionate (496.2 mg, 2.85 mmol) were added to the solution of MB, stirring at 50 °C. 
When the mixture turned to yellow, after 30 min, the toluene phase containing leuco-MB 
was transferred dropwise over 60 min into a solution of p-nitrobenzyl chloroformate 
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dissolved in 40 mL of toluene, maintained in an ice bath. After overnight reaction at 
room temperature, the mixture was collected after washing with water three times. The 
obtained organic phase was evaporated under reduced pressure and then was precipitated 
into cold methanol. The precipitates were purified by recrystallization from acetonitrile 
yielding orange solid powder: yield (52.25 mg, 11.24%): 1H NMR (400 MHz, CDCl3) δ 
8.21 (d, J = 8.4 Hz, 2H), 7.47 (d, J = 8.3 Hz, 2H), 7.36 (d, J = 8.6 Hz, 2H), 6.70 (d, J = 
2.5 Hz, 2H), 6.64 (dd, J = 8.9, 2.3 Hz, 2H), 5.32 (s, 2H), 2.96 (s, 12H), 1.57 (s, 2H). 
Found C, 61.88; H, 5.10; N, 12.06. Calcd for C24H24N4O4S: C, 62.05; H, 5.21; N, 12.06 
 
4.2.3. Spectroscopic assessment  
 All spectroscopic measurements were performed in 10 mM phosphate buffered 
saline solution (PBS, pH 7.4, 1% DMSO). For the spectrometer measurements, a quartz 
cuvette with 1 cm path length was used to hold each sample. The absorbance of the 
solution was measured using a Genesys 6 spectrophotometer (Thermo Fisher Scientific, 
Inc., USA). Fluorescence spectra were acquired both using a PerkinElmer LS55 
fluorescence spectrometer (Massachusetts) and an inverted microscope setup. A 
wavelength of 580 nm was chosen as the excitation source and fluorescence was detected 
in a wavelength range between 640 and 800 nm. The heterogeneity of the sample was 
probed using an inverted Nikon TE200U microscope with a 10x objective (NA = 1.4). 
The 514.5 nm laser line of an Ar+ ion laser (~500 µW) was used to excite the sample, 
which was deposited on plasma cleaned glass coverslips. An Acton SP2500 spectrograph 
with a 150 grooves mm-1 grating was employed to disperse the emission and a Princeton 
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Instruments ProEM 1024 EMCCD camera was used to record the fluorescence emission 
between 620 and 800 nm.  
 
4.2.4. Spectral analysis of p-NBMB 
 The solutions of p-NBMB (1 µM) in deionized water (1% DMSO) were prepared 
to assess spectral analysis of p-NBMB. The fluorescence and absorbance of p-NBMB 
was evaluated using a UV-Visible spectrophotometer and fluorescence spectrometer, 
respectively, along with MB (1 µM) as a reference.  
 
4.2.5. Nitroreductase activity assay 
 p-NBMB was dissolved in DMSO to obtain a stock solution of 10 mM and the 
stock solution was diluted to achieve concentrations ranging from 1 µM to 100 µM. 
Nitroreductase was mixed to dilute p-NBMB solution with an enzyme assay buffer (1 
mM NAD(P)H, PBS) containing 1% DMSO to achieve final enzyme concentrations of 1 
unit mL-1 and 2 units mL-1. All prepared samples were incubated at 37 °C. Fluorescence 
spectra were measured with/without nitroreductase, changing the concentration of 
imaging probe and enzyme. Fluorescent images were obtained using IVIS Spectrum 
(Caliper Life Sciences, Perkin Elmer). Excitation light of 640 +/- 17 nm was used, and 
fluorescence emission was collected at 800 +/- 10 nm (Auto exposure, F stop 2, small 
binning). Mean fluorescence radiant efficiency was obtained for each well using Living 
Image Software (Caliper Life Sciences). 
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4.2.6. E. coli assay  
 E. coli XL1-Blue were grown in 3 mL of terrific broth without antibiotic 
overnight at 37 °C.  At the end of the incubation, the bacteria were centrifuged at 2000xg 
for 10 minutes at 4 °C. The bacterial pellet was resuspended in 1 mL of PBS containing 
1% DMSO. To investigate the fluorescent response of p-NBMB to intact E. coli, bacteria 
(approximately 109 CFU mL-1) were added to each well of a black 96 well plate. 
Afterward, p-NBMB was added to a final concentration of 1 – 50 µM to each well of the 
96 well plate. In addition, fluorescence response of p-NBMB to serial number of E. coli 
was examined. The bacterial suspension (approximately 109 CFU mL-1) was serially 
diluted in PBS containing 1% DMSO in the following concentrations: undiluted, 1/10, 
1/102, and 1/103.  100 µL of PBS containing 1% DMSO, undiluted, and diluted bacterial 
suspension were transferred to a black 96 well plate containing 50 µM of p-NBMB and 
incubated at 37 °C for 4 hours. After the treatment, these well plates were incubated at 37 
°C for 4 hours. At the end of the incubation, the fluorescence intensity was monitored in 
the same manner as for the measurement in section “Fluorescence imaging”. To calculate 
the bacterial number, the same bacterial suspension was used. 100 µL from each dilution 
was spread on agar plates without antibiotics and incubated at 37 °C overnight. The 
colonies were counted from each plate, and colony numbers were used to calculate 
colony forming units (CFU) per mL in the original bacterial suspension.  
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4.2.7. Singlet oxygen (1O2) generation  
 Singlet oxygen generated from p-NBMB solution was monitored by oxidation of 
p-nitrosodimethylaniline (RNO).1 It is known that RNO is bleached in the presence of 
singlet oxygen, implying that the change in the intensity of RNO absorbance indicates 
1O2 generation.1 A solution of p-NBMB (10 µM) was prepared with the enzyme assay 
buffer containing 2 unit mL-1 of NTR and 1 mM of NAD(P)H. The buffer solution 
without the redox enzyme was used as a negative control. After incubation of all prepared 
samples for various time intervals ranging from 3 h to 24 h at 37 °C, RNO (13.2 µM) and 
histidine (21 mM) were added to the solutions. Those solutions were irradiated with a He-
Ne laser (632 nm, 110 mW/cm2, Hughes Research Laboratories, Culver City, CA). 
Various irradiation times ranging from 10 to 75 min were used to determine the effect of 
irradiation time on 1O2. The optical density at 440 nm (λmax of RNO) was monitored 
using a UV-visible spectrophotometer. 
 
4.3. RESULT AND DISCUSSION 
 The caged NIR fluorescent probe p-NBMB was synthesized in straightforward 
steps using MB and p-nitrobenzyl as shown in Scheme 4.2.. Initially, MB in toluene 
(80% v/v in water) was reduced to obtain the activated leuco form of MB (leuco-MB). 
The yellow toluene phase containing leuco-MB was transferred into 4-nitrobenzyl 
chloroformate in toluene to afford the caged p-NBMB. The orange solid resultant p-
NBMB was characterized by elemental analysis and 1H-NMR spectroscopy. The proton 
NMR of p-NBMB in CDCl3 in Fig. 4.1. showed all the characteristic peaks and splitting, 
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which indicated successful p-NBMB synthesis. The chemical shift value of the two 
protons after the reaction was deshielded from 4.82 ppm to 5.32 ppm, which is indicative 
of the formation of the carbamate bond.  
  
Scheme 4.2. Synthetic schemes of fluorescent probe p-NBMB. Reagents and 
conditions: (i) methylene blue, Sodium dithionate, Sodium bicarbonate, H2O/Toluene, 
50 °C, 1 h; (ii) Leuco Methylene blue, 4-nitrobenzyl chloroformate, dry toluene,(1) 0 
°C, (2) Overnight. 
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Figure 4.1. 1H NMR spectrum of p-NBMB in CDCl3. 
 
 The spectral analysis of p-NBMB was compared with that of a fluorophore MB as 
a reference. In spectroscopic evaluation of MB and p-NBMB, MB exhibits maximal 
absorbance at 665 nm and fluorescence at 685 nm (λex = 665 nm) (Fig. 4.2). In contrast, 
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p-NBMB displayed neither significant absorbance nor fluorescence excitation at 665 nm. 
This phenomenon appears to be caused by the interruption of π-conjugation system 
bridging the three rings of MB, which quenches the absorbance between 500 nm to 800 
nm. This result indicated that p-NBMB exhibits no fluorescence when the signal 
compound MB is caged with the nitrobenzyl moiety redox switch as illustrated in 
Scheme 4.1, which should lead to diminished noise in clinical imaging applications.  
 
   
 
Figure 4.2. Absorbance spectra of imaging probe p-NBMB (dashed line) and MB 
(solid line) as a reference by UV spectroscopy. 
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Figure 4. 3. Change in fluorescence intensity of p-NBMB (10 µM) after 3, 6, 9, 12, and 
24 hours of incubation with NTR (1 unit mL-1)/NAD(P)H (1 mM). The negative control 
did not include the enzyme and NAD(P)H. Spectra were acquired in 10 mM PBS, pH 7.4 
with the excitation at 580 nm. 
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 The selective uncaging via nitro reduction was assessed using NfsA, which is the 
major NTR from E. coli. As expected, p-NBMB exhibited a selective response for NTR, 
shown in Figure 4.3. The fluorescence spectrum of the control revealed no emission 
between 640 and 800 nm when excited by either 580 nm light using a fluorescence 
spectrometer or by 514.5 nm laser light, unless NTR is added in the solution. 
Heterogeneities of reduced p-NBMB were further observed with thin film fluorescence 
emission spectra as shown in Fig. 4.4. After reduction of p-NBMB by NTR, several 
different peaks were recovered in addition to the dominant 680 nm peak in the spectrum 
(Fig. 4.4.). These results might be due to the formation of aggregates and excimers when 
the reduced p-NBMB interacts with the surface of a glass cover slip. A previous reported 
 
Figure 4.4. Heterogeneity of p-NBMB in addition of NTR (1 unit) with NAD(P)H (1 
mM).  Thin ﬁlm ﬂuorescence emission spectra were obtained at 541 nm excitation. 
108 
 
study also showed that the fluorophore MB forms dimers in dilute aqueous solutions and 
aggregates at increasing concentration due to the strong π-interactions among MB 
molecules.112 Thus, peaks from dimer and aggregates would appear on the longer 
wavelength at 712 nm and 728 nm due to the transition dipole moment from the ground 
state to the lower excited state, called the N-branch.113 Considering the increase in 
fluorescence intensity in the presence of NTR, we anticipate that uncaging p-NBMB is 
dependent on nitroreductase-mediated two-electron reduction of the nitrobenzyl moiety 
redox switch. 
 To verify whether there is a fluorescence response to other redox enzymes, which 
catalyze two-electron reduction, p-NBMB emission was investigated using DT-
diaphorase. As shown in Fig. 4.5., DT-diaphorase did not induce any noticeable 
fluorescence signal enhancement from p-NBMB compared to the negative control 
without the enzyme, over an incubation period up to 48 h. According to previous studies 
on triggerable fluorescent probes, nitrobenzimidazoles containing aryl nitro groups  could 
be an efficient redox switch that can be turned on by DT-diaphorase.114 In addition, 
CB1954, the aforementioned prodrug carrying aryl nitro groups, was found to be 
activated by both DT-diaphorase and NTR but NTR catalyzed the reduction of CB1954 
60 times faster than DT-diaphorase.35, 115 However, caged p-NBMB with the p-
nitrobenzyl modification on the phenothiazine ring was not activated by DT-diaphorase. 
The result indicated that p-NBMB can be selectively reduced in the presence of NTR and 
hence can be used for NTR detection.   
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Figure 4.5. Fluorescence intensity of p-NBMB (10 µM) treated with redox enzymes. 
Negative control did not include enzymes and NAD(P)H  
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Figure 4.6. Fluorescence spectra of p-NBMB (1 µM, 10 µM, 100 µM) with NTR (1 unit) 
in the presence of NAD(P)H (1 mM) and the negative control without NTR. Spectra were 
acquired in 10 mM PBS, pH 7.4 with the excitation at 580 nm. 
 
 We also examined changes in fluorescence intensity as a function of 
concentration of p-NBMB, following incubation with one unit per mL of NTR. An 
increase in fluorescence intensity was observed when the concentration of p-NBMB was 
increased from 1 to 10 to 100 µM (Fig. 4.6.). This result indicates that fluorescence 
enhancement is dependent on reduction of a p-nitrobenzyl redox switch by NTR. 
However, based on qualitative interpretation, the fluorescence intensity was not 
proportional to the concentration of p-NBMB within the concentration range. From this 
result, we inferred that the fluorescence enhancement would be more related to the 
amount of NTR. Hence, two concentrations of NTR, 1 unit mL-1 and 2 units mL-1, were 
tested to observe the redox enzyme capacity in releasing fluorophore MB from p-NBMB 
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(Fig. 4.7.). At the lowest p-NBMB concentration, 1 µM, the higher fluorescence emission 
intensity was similar, regardless of NTR concentrations. This implies that p-NBMB 
might show a detection limit at p-NBMB concentrations higher than 1 µM. For better 
visualization, we investigated the imaging capacity of p-NBMB using an in vivo imaging 
system, a Xenogen IVIS® Spectrum. As expected from the result showing NTR 
dependent fluorescence release in Fig. 4.8., images obtained from IVIS® are consistent. 
When the fluorescence intensity was compared by the released radiance efficiency in 
vivo, there were no statistically significant differences between the two p-NBMB 
concentrations. These results suggest that fluorescence emission occurring by p-NBMB 
 
Figure 4.7. Fluorescence intensity from p-NBMB at a concentration of 1 µM, 10 µM 
and 100 µM. The samples were incubated at 37 °C overnight in PBS buffer (pH 7.4) 
containing NTR (1 unit mL-1 and 2 units mL-1) 
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reduction was predominantly dependent on the reduction capacity of NTR in the presence 
of NAD(P)H, providing its potential use for monitoring NTR.  
 
Figure 4.8. Fluorescence response of p-NBMB to nitroreductase. (a) IVIS fluorescence 
images of p-NBMB (10 µM, 100 µM) with nitroreductase (1 and 2 unit mL-1, 1 mM 
NAD(P)H) and the control without nitroreductase. (b) Quantitation of fluorescence from 
each group. Data shown as mean ± SD (n = 3). Spectra were acquired after incubation at 
37 °C overnight in 10 mM PBS (pH 7.4). 
  
 Since we are interested in p-NBMB application not only in NTR activatable 
imaging in vitro but also for therapeutic purposes, we primarily focused on the 
characterization of the NTR selectivity of p-NBMB. This can be eventually translated 
into therapeutic advances in photodynamic therapy using fluorophores. Hence, we further 
examined the fluorescence response of p-NBMB to intact E. coli K12 strain XL1-Blue. 
When incubated with 109 CFU mL-1 of E. coli, the NIR fluorescent probe p-NBMB was 
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activated and released a fluorophore showing emission as indicated in the images in Fig. 
4.9 (A). In addition, p-NBMB demonstrated a concentration dependent increase in 
fluorescence intensity in the presence of bacteria. When the p-NBMB concentration is 1 
µM as this bacterial concentration, no noticeable change in fluorescence emission was 
observed, indicating that the detection limit is 1 µM. This result is consistent with Fig. 
4.7. We also used a serial dilution of a bacterial suspension to determine in vitro 
sensitivity of p-NBMB fluorescence to bacterial number. As shown in Fig. 4.9., the raw 
fluorescence images and the quantified data indicated that fluorescence intensity from p-
NBMB is correlated with an increase in bacterial number. At the concentration and 
incubation time shown, the detection limit ranged between 107 and 108 CFU mL-1. 
However, optimizing concentration of p-NBMB and incubation time could likely 
increase this limit. These observations implied that E. coli expressing NTR activates 
reduction of a redox switch in p-NBMB to facilitate release of a fluorophore, MB. 
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Figure 4.9. (A) IVIS fluorescence images of p-NBMB (1 - 50 µM) incubated with intact E. 
coli K12 strain XL1-Blue (109 CFU mL-1) at 37 °C for 4 hours. (B) Sensitivity of p-NBMB 
fluorescence to bacterial number. IVIS fluorescence images of p-NBMB (50 µM) 
incubated with a serial dilution of the intact E. coli K12 strain XL1-Blue suspension at 37 
°C for 4 hours. 
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Figure 4.10. Singlet oxygen (1O2) generation from p-NBMB solution (A) with or (B) 
without NTR/NAD(P)H was monitored using p-nitrosodimethylaniline (RNO) upon laser 
light irradiation at a wavelength of 632 nm. Various irradiation times ranging from 10 to 
75 min were used to determine the effect of irradiation time on singlet oxygen 
production. The concentration of p-NBMB was 10 µM in the enzyme assay buffer 
containing NTR at a concentration of 2 units mL-1 and NAD(P)H at a concentration of 1 
mM. The intensity of RNO absorbance decreased in the p-NBMB solution containing 
NTR/NAD(P)H while the solution without the redox enzyme did not affect RNO 
absorbance. 
 
 Along with the capacity of p-NBMB for imaging anaerobic bacteria expressing 
NTR, p-NBMB might be useful for the detection of hypoxia in application for tumor 
diagnosis based on the recently reported studies demonstrating that molecular probes 
caged with nitrobenzyl group showed fluorescence enhancement in hypoxia condition 
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(1% pO2).116 Moreover, since the fluorophore methylene blue is an effective 
photosensitizer for photodynamic therapy, the generation of singlet oxygen (1O2) from p-
NBMB was tested using p-nitrosodimethylaniline (RNO) before and after activation by 
NTR. It is known that RNO is bleached in the presence of single oxygen, implying that 
the change in RNO absorbance intensity indicates the generation of 1O2.16 Figure 4.10.(A) 
shows that the p-NBMB incubated with NTR/NAD(P)H exhibited a decrease in RNO 
absorbance after laser irradiation at a wavelength of 634 nm (110 mW/cm2, Hughes 
Research Laboratories, Culver City, CA). In contrast, no significant change in RNO 
absorbance was observed from the control after laser exposure (Fig. 4.10.(B)). This result 
indicated that free MB released from p-NBMB reduction was able to generate 1O2 upon 
an irradiation in a NIR range.  Based on the work done by Komine et al. demonstrating  
that 1O2 generated from MB (0.01%) with a laser irradiation for 5 min killed E. faecalis 
(>99.9%)117, p-NBMB will be beneficial both for targeted diagnostic and therapeutic 
applications.  
  
 
4.4. CONCLUSIONS 
    We have developed a new NIR fluorescent probe p-NBMB equipped with a p-
nitrobenzyl redox switch that enables selective switching on of fluorescence by NTR. 
Whereas p-NBMB shows no fluorescence emission in PBS buffer at pH 7.4, it exhibits 
remarkable NIR fluorescence intensity after undergoing selective reduction by NTR. 
Furthermore, p-NBMB fluorescence was induced by incubation with live E. coli bacteria, 
117 
 
indicating that endogenous NTR can activate the nitrobenzyl moiety switch to generate 
the fluorophore. This collectively indicates that p-NBMB would be a suitable imaging 
sensor to detect bacteria expressing NTR. In addition, p-NBMB also possesses potential 
as an MB prodrug which can be applied for the treatment of various diseases.  
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 Incorporation of redox-responsive functionality, which are a QPA trigger and a 
nitrobenzyl trigger, into polymer and fluorophore, respectively, yield the materials with a 
redox-responsive property. We have accomplished to obtain the novel redox-responsive 
polymeric nanoparticles and micelles using a QPA redox trigger for targeted drug 
delivery. We also achieved the synthesis of the new NTR activatable NIR fluorescent 
probe caged by nitrobenzyl redox trigger for its selective imaging and therapy. In this 
chapter, we summarize dissertation research work consisting of those two materials 
prepared from redox triggers and discuss their challenges and future research directions. 
 Redox-responsive polymer was synthesized with a QPA trigger and utilized for 
the preparation of redox-responsive NPs. These NPs enabled to release incorporated drug 
triggered by stimulated redox-state using sodium dithionite. These NPs, however, were 
noticeably aggregated in aqueous environment because of hydrophobic nature of the 
polymer. Since PEG grafting has been established as a vital alternative to overcome 
various in vitro/in vivo stability issues of NPs, we adopted this approach to yield redox-
responsive amphiphilic copolymer to improve the polymeric NPs. After successful 
mPEG grafting to the redox-sensitive hydrophobic polymer, polyQPA-mPEG became to 
be water soluble as well as self-assembled as micelles. In vitro PTX release kinetics has 
shown that PTX-loaded redox-responsive polyQPA-mPEG micelles were stable in 
aqueous environments and able to release the loaded PTX by redox-triggered QPA 
reduction which disrupted micelle structure. During the study on reducing enzyme-
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mediated lactone release from redox-responsive micelles, we found that hydrophilic PEG 
blocks might contribute to increasing water solubility of polyQPA, thereby facilitating 
the binding between the enzyme and QPA triggers on the polymer. Therefore, the 
relationships between the structures of the QPA based polymer/monomer and its 
reduction activity as substrates of DT-diaphorase are needed to be explored for the 
optimization. The modification of polymers for further application in targeted delivery 
might be more easily achieved afterward.  
 We also successfully synthesized a nitroreductase-triggered near infrared 
fluorescent probe. Conjugating methylene blue with a redox trigger enables the 
fluorescent probe to be activated by 1,6-elimination in the presence of nitroreductase, 
resulting in the release of methylene blue fluorophore. We also found that MB release 
after the reduction of a probe could produce singlet oxygen, indicating that its potential 
use as a therapeutic tool. In the future, kinetics of photoxygeneration of this probe needs 
to be evaluated. The photosensitizing efficacy of this probe on viruses, yeasts, and 
protozoa also can be conducted for a its wide variety of applications. 
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